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Zusammenfassung 
SNAP25 (Synaptosomal assoziiertes Protein, 25 kDa; Teil des SNARE Komplexes) ist an 
der Fusion von synaptischen Vesikeln mit der präsynaptischen Zellmembran beteiligt, und 
somit notwendig für die Regulation der Neurotransmitter-Ausschüttung. Außerdem wird 
eine wichtige Funktion bei dem Wachstum von Axonen und synaptischer Plastizität 
diskutiert. In Humanstudien wurden wiederholt verschiedene Einzelnukleotid-
polymorphismen von SNAP25 mit Aufmerksamkeitsdefizit- / Hyperaktivitätssyndrom (ADHS) 
assoziiert. In der vorliegenden Studie wurden heterozygote Snap25 knockout Mäuse als 
Modell für ADHS untersucht. 
Heterozygote (+/-) Snap25 knockout Mäuse und ihre wildtypischen Wurfgeschwister 
wurden unter Kontrollbedingungen großgezogen oder einer maternalen Separation (MS) 
unterzogen. Beginnend im Alter von etwa 2 Monaten wurden diese Mäuse verschiedenen 
Verhaltenstests unterzogen: in einem wiederholten Langzeit-Open-Field (OF) Test wurde 
Aktivität untersucht, Aufmerksamkeitsdefizite und Impulsivität mit dem 5 Choice Serial 
Reaction Time Task (5CSRTT), angst-ähnliches Verhalten in der Light-Dark Box (LDB) und 
depressions-ähnliches Verhalten im Porsolt Forced Swim Test (FST). Die Gehirne dieser 
Mäuse wurden anschließend auf die Expression verschiedener ADHS bezogener Gene in 
einer quantitativen Real-Time-PCR (qRT-PCR) untersucht. Eine zusätzliche Gruppe weiblicher 
Mäuse (+/+; +/-) durchlief einen einstündigen OF Test nach oraler Gabe von 45 mg/kg 
Methylphenidat (MPH) oder Placebo. 
Um eine optimale Dosierung für MPH in diesem Experiment zu finden, wurde eine 
Pilotstudie durchgeführt. Hierbei wurden wildtypische C57/BL6 Mäuse in einem Langzeit OF 
Test mit Gabe unterschiedlicher Dosierungen von MPH, sowohl oral als auch intraperitoneal 
(i.p.), untersucht. Im Anschluss wurden die Gehirne dieser Tiere auf Neurotransmitter-
konzentration geprüft. Diese Pilotstudie ergab als optimale Dosierungen von MPH auf 
Verhaltensebene 7.5-15 mg/kg i.p. und 30-60 mg/kg oral. Allerdings waren die 
neurochemischen Effekte der beiden unterschiedlichen Applikationsarten größtenteils 
verschieden. 
In der Snap25 Studie zeigten ungestresste Kontroll-Tiere einen leicht hyperaktiven 
Phänotyp in dem zweiten von zwei Langzeit-Open-Field Tests (60 min) im Abstand von 3 
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Wochen. Bei Betrachtung aller Gruppen ergab sich auch eine signifikante Interaktion von 
Stress und Genotyp in der zweiten Testung, und zwar dahingehend, dass MS Tiere 
grundsätzlich aktiveres Verhalten zeigten, ohne Genotypen-Unterschiede. In der 
Anfangsphase des 5CSRTT lagen nur signifikante Haupteffekte für Stress vor, gestresste Tiere 
hatten größere Probleme im Meistern der Aufgabe als Wildtypen. Erst im sogenannten Test-
Trial am Ende der Versuchsreihe ergaben sich signifikante Haupteffekte für den Genotyp. 
Heterozygote Snap25 knockout Mäuse zeigten beispielsweise weniger korrekte Reaktionen 
und konsumierten auch weniger Belohnungspellets direkt im Anschluss an eine korrekte 
Reaktion als Wildtypen. In der LDB brauchten +/- Mäuse wiederum weniger Zeit als 
Wildtypen, um den erleuchteten Teil der Arena zu betreten, und zeigten dadurch ein 
reduziertes Angst-ähnliches Verhalten. Im Gegensatz dazu ergab sich ein erhöht 
Depressions-ähnliches Verhalten für männliche heterozygote Snap25 knockout Mäuse im 
FST. Auf der Genexpressions-Ebene hatten +/- Mäuse niedrigere Expressionslevels von Maoa 
und Comt und höhere Expressionslevels von Nos1 als Wildtypen. Abschließend zeigte sich 
eine erhöhte Reaktion auf MPH bei heterozygoten Mäusen. 
Zusammenfassend zeigen heterozygote Snap25 knockout Mäuse einige 
Charakteristika von ADHS auf Verhaltensebene, wie zum Beispiel eine leichte Hyperaktivität 
in bekannter Umgebung, Schwierigkeiten im Erlernen einer gestellten Aufgabe und sogar 
Verhaltensweisen, die auf eine Abneigung gegenüber Verzögerungen hindeuten. Zusätzlich 
kommt es aufgrund des Knockouts zu veränderten Expressionslevels verschiedener ADHS 
assoziierter Gene. Auch wenn die erhöhte Verhaltensreaktion von +/- Mäusen auf MPH nicht 
die erwartete Reaktion eines ADHS Modells darstellt, deutet sie dennoch auf ein 
Ungleichgewicht des dopaminergen Systems im Gehirn hin, das bei ADHS eine wichtige Rolle 
spielt. 
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Summary 
SNAP25 (Synaptosomal-Associated Protein of 25 kDa; part of the SNARE complex) is 
involved in the docking and fusion of synaptic vesicles in presynaptic neurons necessary for 
the regulation of neurotransmitter release, as well as in axonal growth and synaptic 
plasticity. In humans, different single nucleotide polymorphisms of SNAP25 have repeatedly 
been associated with attention deficit/hyperactivity disorder (ADHD). Thus, in this study 
heterozygous Snap25 knockout mice were investigated as a model of ADHD. 
Heterozygous (+/-) Snap25 knockout mice as well as their wild-type (+/+) littermates 
were reared under control conditions or underwent a Maternal Separation (MS) procedure. 
Starting at the age of 2 months, mice were tested for locomotor activity in a repeated long-
term Open Field (OF) task, for attention deficits and impulsive behavior in the 5 Choice Serial 
Reaction Time Task (5CSRTT), for anxiety-like behavior in the Light-Dark Box (LDB) and for 
depression-like behavior in the Porsolt Forced Swim Test (FST). The brains of these mice 
were subsequently tested for the expression of several ADHD related genes in a quantitative 
Real-Time PCR (qRT-PCR) study. Another group of female mice (+/+; +/-) underwent a one 
hour OF test after oral administration of 45 mg/kg Methylphenidate (MPH) or placebo. 
To find an optimized dosage for this MPH challenge, a pilot study was performed. 
Wild-type C57BL/6 mice were tested in a long-term OF with several dosages of MPH both 
intraperitoneally (i.p.) and orally. The brains of these animals were afterwards investigated 
for neurotransmitter concentrations. In this pilot study the dosages of MPH that were 
similarly behaviorally effective without causing symptoms of overdosing were 7.5-15 mg/kg 
intraperitoneally and 30-60 mg/kg orally. However, even though it was possible to find 
intraperitoneal and oral doses that correlate behaviorally, the neurochemistry was mostly 
different. 
In the study on Snap25-deficient mice, unstressed controls showed a hyperactive 
phenotype in the second of two long-term OF sessions (60 min) spaced three weeks apart. 
Considering all groups, there was a significant interaction of stress and genotype in the 
second session, with animals subjected to MS being overall hyperactive with no genotype 
differences. In the training phase of the 5CSRTT only effects of stress were found, with MS 
animals finding and consuming fewer rewards. In the single test trial, several genotype 
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effects became apparent, with tendencies for the number of correct nose pokes and the 
number of rewards eaten, and a significant effect for the number of rewards eaten directly 
after the correct response. In all of these variables +/- mice performed worse than their wild-
type littermates. In the LDB +/- mice entered the lit compartment of the arena earlier than 
the controls, thus showing attenuated anxiety-like behavior. Regarding depressive-like 
behavior in the FST, male +/- mice spent significantly less time struggling than male +/+ 
mice. In the gene expression study, +/- mice had lower expression levels of Maoa and Comt, 
and higher expression levels of Nos1 than wild-types. Finally, the locomotor activity 
response to MPH was exaggerated in +/- mice as compared to controls. 
Heterozygous Snap25 knockout mice show some of the behavioral characteristics of 
ADHD, as for example a mild hyperactivity in a familiar environment, difficulties in the 
correct execution of a given task and even some behavior that can be interpreted as delay 
aversion. Additionally, expression levels of three ADHD related genes were changed in these 
animals. Although the exaggerated locomotor activity response to MPH is not to be 
expected of an ADHD model, the difference in the response between +/+ and +/- mice 
nonetheless implicates a potential dysfunction of the brain dopaminergic system. 
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1 Introduction 
1.1 Animal models of psychiatric disorders 
1.1.1 What is an animal model? 
There are hardly any scientific definitions to be found of what constitutes an animal 
model, although the subject is much discussed and opinions are manifold. In 1984, William 
McKinney, who contributed much to the theoretical background of what today is perceived 
as good scientific practice in animal research, put it like this: “Animal models represent 
experimental preparations developed in one species for the purpose of studying phenomena 
occurring in another species” (McKinney, 1984). As simple as this definition sounds, it entails 
more than is initially obvious and still holds true today. 
1.1.2 Criteria for good animal models 
In 1969, McKinney and Bunney argued for the importance of finding an animal model 
of depression (McKinney & Bunney, 1969). In this paper, they also proposed set of criteria 
for animal models of human mental disorders in general, namely that the model should 
resemble the condition it models in its etiology, biochemistry, symptomatology and 
treatment. 15 years later, several possible animal models of depression had been published 
and Paul Willner reviewed them in relation to three sets of validating criteria that were 
based on the criteria proposed by McKinney and Bunney. According to Willner, a perfect 
animal model should fulfill 3 forms of validity. Predictive validity is assessed by whether a 
model correctly identifies pharmacological treatment with a comparable clinical potency and 
without making errors of omission or commission. Face validity is assessed by whether the 
model resembles the disorder in a number of respects. Finally, construct validity is assessed 
by whether both the behavior in the model and the features of the disorder can be 
unambiguously interpreted, and are homologous and whether the feature being modelled 
stands in an established empirical and theoretical relationship to the disorder (Willner, 
1984). Although 30 years have passed since these criteria were proposed, every animal 
researcher in the world is aware of their importance today. 
1.1.3 Genetic mouse models of psychiatric disorders 
There are several ways to come by an animal model of a (psychiatric) disorder. One is 
to pharmacologically induce a certain phenotype, for example by injecting an animal with an 
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agonist or antagonist to a specific receptor in the brain which has been previously associated 
with a certain disorder (Hashmi et al., 2014). Another is to screen a population of animals for 
a specific phenotype, then to selectively breed the top and the bottom percentiles of this 
phenotype and to continue this for some generations (Carroll et al., 2008). However, the 
most common type nowadays is the genetic animal (or mouse) model, whose genome has 
been randomly (by chemical mutagenesis) or, more frequently, specifically altered for genes 
that have been associated with psychiatric disorders. This can either be done by adding 
another gene, thus making the animal transgenic, through microinjection into the male 
pronucleus of a fertilized mouse (McKnight et al., 1983), or by specifically inactivating a gene 
by targeting it through homologous recombination and thus producing a knockout mouse 
(Osada & Maeda, 1998). 
1.2 SNAP25 and its relevance for psychiatric disorders 
1.2.1 Neurobiology of SNAP25 
Snap25 was first discovered as a neuron-specific mRNA in the mouse brain and found 
to be predominately localized in nerve terminals (Branks & Wilson, 1986). The human 
SNAP25 gene was first cloned in 1994 and found to be highly and specifically expressed in 
the adult brain (Zhao et al., 1994). SNAP stands for “synaptosomal associated protein” and 
the 25 for its atomic mass of 25 kDa. It codes for a 206 amino acid long SNARE protein 
(soluble NSF attachment protein receptor where NSF stands for N-ethyl-maleimide-sensitive 
fusion protein) and as such has been implicated in most intracellular membrane trafficking 
events studied so far (Chen & Scheller, 2001). Together with syntaxin and the vesicle-
associated membrane protein (VAMP, also called synaptobrevin) it was one of the first 
SNARE proteins discovered. Chen and Scheller’s (2001) model of exocytosis (Figure 1) states 
that after the dissociation of n-Sec1 from syntaxin (possibly mediated by Rab proteins), the 
binding of the three neuronal SNAREs syntaxin, VAMP and SNAP25 (localized at the 
presynaptic plasma membrane of neurons) can occur. Syntaxin, VAMP and SNAP25 are 
helical proteins and together form a heterotrimer, arranged in parallel (Sutton et al., 1998; 
Figure 2). Full zipping of the coiled-coil complex is triggered by Ca2+, which results in 
membrane fusion and release of vesicle contents into the synaptic cleft. After the fusion 
event, the SNARE complex is dissociated and recycled (Figure 1). 
Introduction 
3 
 
 
Figure 1: Molecular model of vesicle exocytosis (Chen & Scheller, 2001) 
 
 
Figure 2: Backbone ribbon drawing of the SNARE complex; blue: VAMP; red: syntaxin; green: SNAP25b. From 
Sutton, Fasshauer, Jahn & Brunger, 1998. 
There are two isoforms of SNAP25 which result from alternative splicing between the 
two exons 5a and 5b (Bark & Wilson, 1994). SNAP25a is found in earlier developmental 
stages, whereas SNAP25b is dominant in the adult brain (Bark et al., 1995). The two isoforms 
differ by nine amino acids, two of which alter the relative positioning of clustered cysteine 
residues that are sites for posttranslational fatty acetylation implicated in membrane 
anchoring (Bark et al., 1995;.Andersson et al., 2000). Membrane anchoring of SNAP25 is 
needed for the exocytosis functionality of the SNARE complex, which is why SNAP25b is the 
isoform that acts here. 
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1.2.2 Association of SNAP25 with psychiatric disorders 
Taking into account the important role of the SNARE proteins in neurotransmission, it 
is not surprising that the SNAP25 gene, or rather a number of single nucleotide 
polymorphisms (SNPs) within the SNAP25 gene, have repeatedly been associated with 
psychiatric disorders. Among others, schizophrenia (Lochman et al., 2013), Tourette 
syndrome (Gunther et al., 2012) and antisocial personality disorder (Basoglu et al., 2011) 
have been discussed to be connected to changes in SNAP25. Most prominently though, 
attention deficit hyperactivity disorder (ADHD) can be found linked to SNAP25 in literature. 
Though there are studies that were not able to replicate such results (see for example 
Renner et al., 2008 in a German sample) or found only weak effects (Mill et al., 2005 in a 
sample from the UK) there are numerous published that verify a connection between 
SNAP25 and the disorder. For example, positive association has been found in an Irish 
sample (Brophy et al., 2002), a Latin American sample (Gálvez et al., 2014), a Turkish 
(Pazvantoğlu et al., 2013) and a Canadian (Barr et al., 2000) sample. A study published in 
2013 conducted on an Australian post mortem sample even found a reduced expression of 
SNAP25 in the frontal cortex of ADHD patients in addition to a significant haplotype (Hawi et 
al., 2013). To concentrate as many results as possible, a computational analysis of multiple 
data sources using a new ADHD genetic database was conducted in 2012 to prioritize 
candidate genes for ADHD (Chang et al., 2012). The result of this study was a list of 16 
prioritized genes, among which was SNAP25. Something similar had been concluded 6 years 
earlier in a review evaluating 8 candidate genes for ADHD and accepting 7 (including 
SNAP25) as valid (Faraone & Khan, 2006). 
1.2.3 The coloboma mouse 
The coloboma mutant mouse (or Cm/+ mouse) is a radiation mutant with a 
heterozygous mutation on mouse chromosome 2, encompassing Snap25 (Hess et al., 1994). 
When homozygous, this mutation is embryonically lethal. Cm/+ mice display a hyperactive 
phenotype (Hess et al., 1992) that can be rescued with a genetic complementation of 
Snap25, but also pharmacologically with medium doses of amphetamine, but not MPH (Hess 
et al., 1996). In addition to hyperactivity, Cm/+ mice exhibit alterations in neuronal plasticity 
and impaired long-term potentiation (Steffensen et al., 1996), as well as marked deficits in 
Ca2+ dependent dopamine release in the dorsal striatum, implying the nigrostriatal 
dopamine pathway which regulates motor activity (Wilson, 2000). The transgenic rescue of 
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Snap25 not only restores activity levels, but also dopamine-modulated synaptic transmission 
(Steffensen et al., 1999). 
1.2.4 The Snap25 knockout mouse 
In contrast to the coloboma mutant, the Snap25 heterozygous knockout mouse only 
lacks Snap25, which was accomplished by replacing exons 5a and 5b through homologous 
recombination. Although this alteration is also embryonically lethal when homozygous, is 
has been shown that Snap25 is not required for nerve growth, but rather is essential for 
evoked synaptic transmission (Washbourne et al., 2002). The Snap25 heterozygous knockout 
mice have recently been investigated as a model of epilepsy (Corradini et al., 2014) and as a 
model of altered dopamine signaling, making it a potential model for both schizophrenia 
(Oliver & Davies, 2009) and ADHD (Baca et al., 2013). 
1.3 Attention deficit/hyperactivity disorder (ADHD) 
1.3.1 What is ADHD? 
ADHD is one of the most common childhood disorders with a prevalence of 3-5%. 
About half of the affected children show persistent symptoms into adulthood (Renner et al., 
2008). The Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV), 
defines hyperactivity/impulsivity and inattention as the major symptomatic dimensions of 
the disorder. Out of a list of symptoms for both dimensions, 6 have to be met in order to 
justify a diagnosis. Also, several symptoms must have been present prior to the age of 12 
years. In addition to this central symptomatology, ADHD has been shown to be comorbid 
with several other psychiatric disorders. In children, mood disorders, anxiety disorders, 
oppositional defiant disorder and conduct disorder are the most common (Lycett et al., 
2014), whereas in adults the most likely comorbidities are major depressive disorder, social 
phobia and substance abuse (Rucklidge et al., 2014). Since emotional lability can be seen in 
some of these comorbid disorders, for the longest time emotional lability was seen as a 
consequence of ADHD. Today, it has become clearer that emotional dysregulation may play 
a causal role in ADHD symptomatology (Villemonteix et al., 2014). 
1.3.2 Neurobiology and treatment of ADHD 
Imaging studies have strongly implicated frontostriatal dysfunctions in patients 
suffering from ADHD. Additionally, several other regions seem to be involved, as for example 
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the anterior cingulum, the prefrontal cortex, the orbitofrontal cortex, the caudate nucleus, 
the thalamus, the amygdala and the cerebellum (Kasparek et al., 2013). On a molecular level, 
the systems implicated are just as manifold. Studies have shown the dopaminergic, the nor-
/adrenergic, the serotonergic and the cholinergic system to be involved in ADHD (Cortese, 
2012). These systems also reflect the genes that are discussed as candidate genes for the 
disorder, as ADHD has a very high heritability of around 76% (Faraone & Mick, 2010). On the 
monoaminergic level, the genes coding for monoamine oxidase A (MAOA), catechol-O-
methyl transferase (COMT), dopamine receptor 4 (DRD4), the dopamine transporter 
(SLC6A3, DAT), the serotonin transporter (SLC6A4, 5HTT), tryptophan hydroxylase 2 (TPH2) 
and several serotonin receptors, among others, have been shown to be associated with 
ADHD. But there are also candidate genes outside of this group, for example the neuronal 
nitric oxide synthase (NOS1) and, of course, SNAP25 (Banaschewski et al., 2010). 
Even though so many different systems are implicated, the dopaminergic system is 
probably the one that is most discussed in the etiology of ADHD. One reason for this is that 
the most commonly prescribed treatment today is pharmacotherapy with one of two 
psychostimulants. One is Methylphenidate (MPH), a dopamine/noradrenalin reuptake 
inhibitor (Heal & Pierce, 2006), and the other d-Amphetamine, a full agonist of trace amine-
associated receptor 1, which, when activated, inhibits the function of the dopamine-, the 
norepinephrine- and the serotonin-transporter (Lewin et al., 2011). Additionally, the 
selective norepinephrine reuptake inhibitor Atomoxetine is often successfully used, as well 
as several new drugs that are up to now only available in the US. PET and SPECT studies 
about the dopaminergic system and its involvement with ADHD have found reduced 
dopamine transporter availability in patients, but are often controversial (Bolea-Alamañac et 
al., 2014). It is not yet fully understood if ADHD is a hyper-dopaminergic disorder, a hypo-
dopaminergic disorder, or both (Ohno, 2003). 
Apart from neurobiological and genetic factors, environmental influences have been 
found to be connected to the etiology of ADHD. Moreover, as with many psychiatric 
disorders, it has been hypothesized that the interplay of genetic and environmental factors, 
so called gene-by-environment interactions (G x E), cause the disorder and not only one or 
the other. In ADHD, the most commonly mentioned environmental influences are fetal 
exposure to smoking or alcohol, exposure to toxins (lead and mercury), pregnancy and 
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delivery complications and psychosocial adversity such as maltreatment or emotional 
trauma (Banerjee et al., 2007). 
1.4 Aim of this thesis 
The aim of this thesis was to evaluate heterozygous Snap25 knockout mice with and 
without stressful experience as a model for ADHD. The main focus thereby lay on altered 
behavior as measured in a number of behavioral tests. The review of literature on SNAP25 
allocates plausible construct validity to this model, as does the fact that human and mouse 
SNAP25 share 95.1% identity at the DNA and 100% identity at the protein level according to 
the NCBI HomoloGene Database. 
Additionally, the normalization of the behavior was tried to accomplish with a 
pharmacological intervention (MPH) to ensure predictive validity. For this end, a pilot study 
was performed to determine a good dose both given orally and injected intraperitoneally 
(i.p.), measuring both locomotor activity and neurotransmitter concentrations in various 
brain regions 100 minutes after the drug application. This was necessary because, first of all, 
i.p. doses for MPH in mice in literature range from 1 mg/kg to 75 mg/kg (Fernández et al., 
2008; Koda et al., 2010; Salahpour et al., 2008; Shuster et al., 1982; Tilley & Gu, 2008; Yan et 
al., 2010) with little inclination as to what constitutes an adequate dose. Secondly, MPH in 
humans is given orally, thus it was tried to establish a non-stressful way of oral application in 
mice through voluntary consumption of a sweet cereal flake infused with MPH. 
A second pilot study was performed to assess the feasibility of the COGITAT 
holeboard test in mice as a measure of attention. The test was rejected for the Snap25 
heterozygous knockout mice project, due to its inability to measure impulsive tendencies. It 
was substituted with the better established 5CSRTT (Carli et al., 1983). 
It was tried to ensure face validity by choosing transferable paradigms and behavioral 
tests. As a stressful environmental factor, MS was used, which is a time-tested method 
proven to alter brain activity, behavior and gene expression (Nishi et al., 2013), in this case 
aimed to model early-life adversities. In addition to the 5CSRTT, which is a reinforced 
learning paradigm initially developed to understand ADHD-like attentional and impulsive 
deficits (Robbins, 2002), a long-term, repeated OF test was used to study locomotor activity, 
in summary covering all three of the core symptoms of ADHD. The OF is a straightforward 
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exploration task of a rectangular or round arena (Walsh & Cummins, 1976). For this 
experiment, the focus was on locomotor activity. 
 
Figure 3: Schematic of the Snap25 study 
 
In addition to testing for core symptoms, different behavioral tests were employed to 
assess the emotionality aspects of the disorder. The LDB, a tool to study anxiety-like 
behavior, measures the conflict between the tendency to explore and the initial tendency to 
avoid the unfamiliar (Bourin & Hascoët, 2003) in a box consisting of an enclosed, dark, safe 
compartment and a larger, brightly lit, more exposed one. To assess depression-like 
behavior, the FST was used (Porsolt et al., 1977). This test is based on the observation that 
when placed in a cylinder containing water, rodents rapidly become immobile after 
unsuccessful attempts to escape. Antidepressants decrease the duration of immobility which 
is used as the main predictor of antidepressant-like behavior (Castagné et al., 2009). Finally, 
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though unsuccessfully, it was tried to assess aggressive behavior with the resident intruder 
paradigm (RI), aimed to test for territorial aggression (Miczek et al., 2001). After the 
behavioral tests, mice were sacrificed and their brains examined for gene expression. Genes 
of interest for this qRT-PCR study were, in addition to Snap25 itself to check for actual 
expression levels as a post-hoc manipulation check, other candidate genes for ADHD to 
check for interactions with other genes. COMT is an enzyme that catalyzes the transfer of a 
methyl group from S-adenosylmethionine to catecholamines, including dopamine and 
norepinephrine. This process is one of the major inactivation pathways for these 
neurotransmitters and thus very important in several diseases in humans (Jiménez-Jiménez 
et al., 2014), including ADHD. Most commonly, the valine/methionine polymorphism in exon 
IV (rs4680) is discussed, though not conclusively, as many studies were not able to replicate 
the initial results (Caylak, 2012). MAOA is responsible for the breakdown of the monoamines 
5HT, NA and DA. In particular, the 4 and 5 repeat alleles of a 30-bp tandem repeat in the 
promoter region is often found to be associated with ADHD (Faraone & Mick, 2010), 
although the gene’s location on the X chromosome makes it susceptible for sexually 
dysmorphic effects (Biederman et al., 2008). DRD2 represents the main autoreceptor of the 
dopaminergic system, but is also critical for postsynaptic transmission (Lindgren et al., 2003). 
The TaqIA1 allele has been associated with ADHD, though also not conclusively (Faraone & 
Mick, 2010). NOS1 is an enzyme predominantly responsible for nitric oxide (NO) production 
in the nervous system, where the gaseous neurotransmitter acts as a biological mediator 
(Zhou & Zhu, 2009). A highly polymorphic dinucleotide repeat in the promoter region of the 
alternative exon 1f of NOS1 (NOS1 ex1f-VNTR) affects brain functioning in schizophrenia 
(Reif et al., 2006) and is also associated with a number of impulsive behaviors and ADHD 
(Reif et al., 2009). Also, a SNP within NOS1 has been connected to quantitative traits in 
childhood ADHD in a genome-wide study (Franke et al., 2009). In addition to taking brains to 
assess expression levels of the above mentioned genes, blood and adrenals were also taken. 
Adrenals were weighed as a measure for stress (David et al., 2013) and blood plasma was 
tested for corticosterone levels. 
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2 Methods 
2.1 MPH study 
2.1.1 Animals 
77 male C57BL/6N mice (7 per group, 11 groups), age-range 6-8 weeks, were 
purchased from Charles River (Sulzfeld, Germany). They were single housed (in Type II 
Makrolon cages) and allowed to habituate to the laboratory for a minimum of 2 weeks 
before testing under controlled temperature (21.6 °C±0.1 °C) and humidity (50.4%±0.5%) 
conditions, under a 12/12h light–dark cycle (lights on at 7AM and lights off at 7PM). Animals 
had unrestricted access to food and water. Each mouse was randomly assigned to one of the 
application-form and dosage groups (7 per group, see Table 1) and put through activity 
testing with drug application within 8 weeks of arriving at the laboratory. Mice were 
sacrificed immediately after the conclusion of the activity testing (within 15 minutes after 
being taken out of the OF), and brains were taken. 
2.1.2 Drugs and application 
MPH (Sigma Aldrich Cat. No. M2892) was dissolved either in physiological saline 
solution or water and then immediately taken for intraperitoneal (i.p.) or oral drug 
administration, respectively. Pure saline solution and water were used for the respective 
0 mg/kg control conditions. For i.p. administration, MPH was diluted in such a way that mice 
had to be injected with 10 µl per gram of bodyweight to achieve the targeted dosage. For 
oral administration, MPH was diluted such that 1 µl per gram of bodyweight had to be put 
on a flake of chocolate flavored cereal (Crownfield Choco Moons; Lidl, Germany) to achieve 
the targeted dosage. Mice from the oral group were familiarized with the cereal for 5 
consecutive days before testing to eliminate novelty effects. 
Table 1: Groups in the MPH dose-response study 
oral 
(in H2O) 
0 mg/kg 10 mg/kg 30 mg/kg 60 mg/kg 90 mg/kg  
intraperitoneal 
(in NaCl) 
0 mg/kg 1 mg/kg 7,5 mg/kg 15 mg/kg 30 mg/kg 45 mg/kg 
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Drugs were administered after baseline activity testing. Animals were taken out of 
the OF and either directly injected with the required dosage (i.p. group), or placed into the 
homecage to be presented with the infused cereal flake (oral group). The different dosages 
for both the oral and the i.p. groups can be found in Table 1. All mice from the oral group 
consumed their cereal flake within 5 minutes after being presented with it and were then 
immediately put back into the OF, the same as the i.p. group after injection. 
2.1.3 Activity testing 
All activity testing was conducted during the first 4 hours of the light phase. The Open 
Field used for activity testing consisted of a quadratic black opaque PERSPEX XT box 
(50×50×40 cm, semi-permeable to infrared light, TSE Systems, Inc., Bad Homburg, Germany). 
The apparatus was illuminated by infrared LEDs from below. Activity monitoring was 
conducted using an infrared sensitive CCD camera and the computer-based video-tracking 
software VideoMot 2 (TSE Systems, Bad Homburg, Germany). 
Mice first underwent 30 minutes of baseline activity testing, after which drugs were 
administered as described above, and were then put back into the Open Field for another 90 
minutes to test for activity under the influence of MPH. The parameter recorded was the 
distance travelled in both the baseline and the testing phase. 
2.1.4 Brain dissection 
Brains were frozen in ice-cold Isopentane (2-Methylbutane, AppliChem GmbH, 
Darmstadt, Germany) and stored at -20 °C until dissection. Dissection was done on a plate 
cooler at -10°C. Regions were dissected by slicing the brains into 6 sections and then excising 
the desired areas (Figure 4). Regions taken were the frontal cortex (prefrontal cortex and 
motor cortex), the striatum including the accumbens nucleus, the hippocampus, and the 
amygdala. After dissection, the different regions were put in 1.5 ml Eppendorf tubes and 
stored at -20 °C until HPLC analysis. The frontal cortex and the striatum went into HPLC as 
primary regions of interest and were weighed on precision scales before further processing. 
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Figure 4: Dissected brain regions for the MPH dose-response study. The upmost picture shows the section 
planes that are specified in the upper left corners of the 6 pictures below. In the lower left corners, the view 
from front or back is specified. MC: motor cortex; PFC: prefrontal cortex; Caud./Put.: striatum (caudate 
nucleus and putamen); N.Acc.: accumbens nucleus; Hippoc.: hippocampus; Amygdala: amygdala region; 
2.1.5 HPLC 
The tissue was diluted 1:20 with buffer containing H3PO4 (150 mM) and DTPA [Bis-(2-
aminoethyl)-amine-N,N,N’,N’’,N’’-penta-acetic acid; 500 µM] and sonicated on ice under 
Argon atmosphere. The homogenate was centrifuged (20 min; 4-8 °C; 19000 rpm) and the 
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supernatant transferred into Eppendorf-caps and stored at -20 °C until analysis. Prior to 
analysis, the thawed homogenate was filtered via a microcentrifugal filter (membrane of 
regenerated cellulose; pore size 0,2 µm; amchro GmbH, Hattersheim, Germany). For 
analysis, the supernatant without further treatment was injected into the HPLC-system, the 
injection volume per sample being 50 µl. The analysis of neurotransmitters and their 
metabolites was performed on an Agilent 1100 HPLC system (Agilent Technologies, 
Waldbronn, Germany) with electrochemical detection (model 1640; BioRad, Munich, 
Germany) according to a previously described method (Riederer & Burger, 2009). If 
saturation of the electrochemical detection system was reached during measurement, the 
injection volume was reduced or the sample was diluted before reinjection. The 
neurotransmitter and metabolites measured were 5HT, DA, NA, 3-Methoxy-4-
hydroxyphenylglycol (MHPG), 3,4-Dihydroxyphenylacetic acid (DOPAC), 
5-Hydroxyindoleacetic acid (5HIAA), and Homovanillic acid (HVA). The parameter recorded 
was nanograms of neurotransmitter or metabolite per gram of brain tissue. For final 
analysis, the three neurotransmitters (DA, 5HT, NA), as well as their respective turnovers 
metabolic turnovers ((HVA + DOPAC) / DA; 5HIAA / 5HT; MHPG / NA) were taken into 
account (Okada et al., 2013). Tissue preparation was done by Esin Candemir and HPLC 
analysis was done by Florian Proft. 
2.1.6 Statistical analysis 
Analysis was done separately for the i.p. and the oral groups, both for the behavioral 
and the neurotransmitter data. For the behavioral data, both the 30 minutes of baseline 
activity and the 90 minutes of experimental activity data were broken down into intervals of 
2 minutes and then evaluated in a Split-Plot ANOVA with “interval” as the within factor and 
“dosage group” as the between factor. For the neurotransmitter analysis, 6 one-way 
ANOVAS were performed for every brain region, with the three neurotransmitters (5HT, NA, 
DA) and their metabolites in relation to them (5HIAA/5HT, MHPG/NA, (HVA + DOPAC)/DA) 
as dependent variables. Dosage group served as independent variable. Post-hoc Scheffé 
tests were performed for dosage group in each analysis. 
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2.2 Pilot Study COGITAT Holeboard System 
2.2.1 Animals 
30 male C57BL/6J mice, age-range 8-10 weeks, were purchased from Charles River 
(Sulzfeld, Germany). They were group housed in groups of 5 upon arrival (in Type III 
Makrolon cages) and were allowed to habituate to the laboratory for a minimum of 2 weeks 
before testing under controlled temperature (21±0.1 °C) and humidity (55±0.5%) conditions, 
under a 12/12h light–dark cycle (lights on at 6 AM and lights off at 6 PM). Animals had 
unrestricted access to food during habituation and to water throughout the experiment. 
Seven days prior to behavioral testing, mice were single housed (in Type II Makrolon cages), 
weighed and put on a restricted diet of 2-3.5 g (plus 2 sugar pellets to get familiarized with 
the reward) of chow per day (depending on the initial body weight), resulting in a weight 
reduction of no more than between 10 and 15%. This feeding protocol was maintained 
throughout the behavioral testing period. 
2.2.2 The COGITAT Holeboard 
During the test period, mice explored a modified COGITAT hole board (Cognitron 
GmbH, Göttingen, Germany; size 660×670 mm, inner surface; Figure 5) bordered by a clear 
plexiglas boundary (height 270 mm) giving access to distal spatial cues. The board contained 
an array of 5 × 5 holes (diameter, 35 mm; distance apart center to center, 127 mm), each 
consisting of a cylindrical tube closed off at its lower end by an adjustable feeding plate 
(50 mm below the upper surface) with a cavity into which a sugar pellet (0.045 g; Bio-Serv, 
Frenchtown, NJ) fits exactly. The colors of the feeding plate and of the food pellet were a 
perfect match. The ground below the feeding plate and the cylindrical tubes was covered 
with vanilla odor (Dr. Oetker™ Pudding powder, Vanilla flavor) to prevent the animals from 
working out the distribution of the pellets by using olfactory stimuli. In one experimental 
run, five of the cylinders were baited with one pellet each. A trial was automatically ended 
after 240 s. During this time, the animals had the opportunity of finding and eating the 5 
food pellets, recognizing the spatial pattern in which the pellets were presented. The system 
uses an infrared system to record different aspects of activity: dips of the head at the upper 
level of the tubes (upper light beam [ulb] 10 mm beneath the upper surface) were 
equivalent to inspections; exploration deep into the hole (lower light beam [llb], 20 mm 
above the level of the pellet), were scored as visits; collections of the pellets by eating them 
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(detected by an infrared light barrier at the level of the pellet). There are manifold, partially 
inter-dependent parameters that can be recorded automatically and simultaneously. Since 
the COGITAT test was in the end not chosen for the G x E study, only two variables from the 
automatic output were selected for presentation here (Table 2) in order to give an 
impression. Additional surveillance with a video camera (VideoMot2, TSE Systems, Bad 
Homburg, Germany) offered the possibility of recording not only the correct path and speed 
of the animals, but also their general level of activity. This variable is also presented here 
(Table 2). Further results can be found in the already published manuscript (Post et al., 
2011). 
Table 2: Variables from the COGITAT Holeboard study discussed 
Parameter Definition/Explanation 
Activity: Total distance travelled 
The total distance (in cm) that each animal travelled per 
trial, as recorded by the VideoMot system 
Acquisition: Pellets eaten The number of pellets eaten in one session 
Errors: Working memory errors, total 
The percentage of the sum of inspections and visits to 
previously baited holes in relation to the total 
 
Figure 5: Schematic drawing of the COGITAT Holeboard system; ulb: upper light beam; llb: lower light beam; 
2.2.3 Drugs and application 
The effects of the non-selective muscarinic antagonist scopolamine and the acetyl-
cholinesterase inhibitor metrifonate on learning and memory in contrast to a sodium 
chloride control group were investigated. Scopolamine hydrochloride, known for its memory 
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impairing effects (Platel & Porsolt, 1982), was dissolved in saline and administered at 
0.05 ml/10 g of bodyweight in a concentration of 0.1 mg/kg subcutaneously. Metrifonate, a 
known spatial memory enhancer (Ikonen et al., 1999), was dissolved in saline and 
administered at 0.1 ml/10 g in a concentration of 50 mg/kg i.p. Each drug was administered 
30 min prior to the daily session. Control animals received a saline injection at a volume of 
0.05 ml/10 g i.p.. Mice were trained for 5 consecutive days and went through 6 trials per 
day. 
2.2.4 Test procedure 
Experiments were carried out between 8 AM and 4 PM. Five holes of the COGITAT 
system were serially baited in an L-shaped pattern with food pellets not visible to the 
animals while moving. Each daily session consisted of six 240 s trials with an inter-trial 
interval of 30 min. Animals were tested in a random order. A trial was completed as soon as 
the animal had collected and eaten all of the pellets within the allotted time span of 240 s or 
when the time span had elapsed, whichever came first. Spatial cues available for the animals 
inside the holeboard enclosure were the entrance with the starting box, the four corners of 
the enclosure, the upper edges of the 25 holes, and the sidewalls for orientation. Outside 
the enclosure, distal cues visible through the transparent Plexiglas walls were a wall, a 
window, a black curtain and a rack with the cages of the remaining experimental animals. In 
the center above the Holeboard the video camera (VideoMot2, TSE Systems, Bad Homburg, 
Germany) was attached. Each animal was subjected to six trials per day. 
2.2.5 Statistical analysis 
For statistical evaluation a repeated measures analysis of variance (ANOVA), with 
Greenhouse-Geisser adjustments (groups and trials as factors), was used for each variable. 
Scheffé tests served as post-hoc-analyses of between group differences. The results are 
displayed as means ± SEMs of the individual trials of the corresponding experimental 
periods. 
2.3 G x E study 
2.3.1 Animals 
38 wild-type (21 males, 17 females) and 38 heterozygous (16 males, 22 females) 
Snap25 knockout animals were used in the G x E behavioral part of this study. For the non-
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stressed control group, animals were bred in the breeding area of the facility and then 
transferred to the behavioral lab, where they were allowed to habituate for 2 weeks before 
the beginning of the behavioral testing (this group consisted of 24 wild-type animals 
(12male, 12 female) and 24 heterozygous animals (12 male, 12 female)). The MS group was 
bred inside the behavioral lab where the early-life stress procedure was carried out for 21 
days, starting directly after birth. After the procedure, at an age of about 25 days, animals 
were weaned and allowed to stay in the behavioral lab until they reached testing age. All 
animals were single housed during testing, starting upon arrival in the behavioral lab for the 
control group and after weaning for the MS group. During breeding and group housing, mice 
were housed in Type III Makrolon cages and in Type II during single housing. One week after 
the conclusion of the behavioral experiments, mice were sacrificed. Blood was taken from 
the from the neck stump (into heparinized blood collection tubes), kept on ice and 
subsequently centrifuged at 3000 g for 5 min at 4 °C. The supernatant containing the plasma 
was then removed and stored at -20 °C until corticosterone analysis at Maastricht University 
(see 2.3.5). Brains were taken, frozen in ice-cold Isopentane and stored at -20 °C until 
dissection. Additionally, adrenals were taken, frozen on dry ice and also stored at -20 °C until 
further analysis. 
For the MPH challenge OF study, another 32 female Snap25 knockout mice (16 wild-
types, 16 heterozygous) were used. They were housed in groups of four (in Type III Makrolon 
cages) and allowed to habituate to the lab for 2 weeks before testing. 
All animals were between 8 and 12 weeks of age when testing began and lived under 
controlled temperature (21.3 ± 0.1 °C) and humidity (50.8 ± 0.5%) conditions, under a 
12/12h light-dark cycle (lights on at 7 AM and lights off at 7 PM) with unrestricted access to 
food (except during the 5CSRTT, see 2.3.3.3.2) and water. 
2.3.2 Early-life stress 
Table 3: Temperature and humidity conditions during the 21-day maternal separation procedure 
PND Temperature Humidity 
1-7 35 ± 5 °C 70 ± 5% 
8-14 30 ± 5 °C 60 ± 5% 
15-21 25 ± 5 °C 50 ± 5% 
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The early-life stress MS paradigm started on post-natal day (PND) 1 (PND 0 being the 
day of birth) and consisted of 3-hour separation sessions on each day from PND1 to PND 21. 
Separation took place in the mornings between 9 and 12. Litters were removed from their 
homecages and put in a Type II cage (with woodchip bedding, cellulose sheets, and an egg 
carton) that they were assigned to for the 21 days of the procedure. Cages were then 
covered with a dampened cloth and heated from above with infrared lamps. Temperature 
and humidity conditions were maintained at certain levels for the different weeks in the 
procedure, starting with high-temperature/high-humidity conditions (mimicking the 
situation in the nest) and slowly working towards normal lab conditions (see Table 3, from 
PND 15 to 21, the dampened cloth was omitted). 
 
2.3.3 Behavioral testing 
2.3.3.1 Long-Term Open Field (OF) 
The OF consisted of a quadratic black opaque PERSPEX XT box (50×50×40 cm, semi-
permeable to infrared light, TSE Systems, Inc., Bad Homburg, Germany). The apparatus was 
illuminated by infrared LEDs from below. Activity monitoring was conducted using an 
infrared sensitive CCD camera and the computer-based video-tracking software VideoMot 2 
(TSE Systems, Bad Homburg, Germany). Mice were individually placed against a 
predetermined retaining wall and behavior was registered for 60 min. Three weeks later, the 
procedure was repeated to test for activity in a more familiar environment. The main 
parameter taken was the distance travelled. After each mouse, the arena was thoroughly 
cleaned with disinfectant. 
2.3.3.2 Light-Dark Box (LDB) 
The rectangular-shaped LDB consisted of a transparent Perspex ‘light’ compartment 
(40x40x27 cm) and a black opaque ‘dark’ compartment (40x20x27 cm). The dark chamber 
contained a small opening at floor level (5x5 cm) and was covered by a removable lid, 
resulting in an almost complete absence of illumination in its interior (0-10 lux). The light 
compartment was uncovered and brightly illuminated (Illumination level of the light 
compartment around 250 lux). Mice were placed into the dark compartment and allowed to 
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freely explore the chamber for 5 min. Parameters recorded were transitions between 
compartments, time spent in the light and time spent in the dark compartment. After the 
test, the chamber was thoroughly cleaned with disinfectant. 
2.3.3.3 Modified 5-Choice Serial-Reaction-Time-Task (5CSRTT) 
2.3.3.3.1 Apparatus 
The apparatus used for the experiment was the 5-hole box from TSE Systems (Bad 
Homburg, Germany; Figure 6). Dustless precision pellets (20 mg, also TSE Systems Inc., Bad 
Homburg, Germany) served as rewards and were delivered directly into the respective target 
hole via pellet dispensers. The house light was generally not illuminated during the testing 
except for time-out periods. The protocol used was adapted from Steckler, Sauvage, & 
Holsboer (2000). 
 
Figure 6: 5 Hole Box (TSE Systems) 
 
2.3.3.3.2 Food restriction protocol 
Depending on their initial weight, mice were given between 2.5 and 3 g of mouse 
chow every day after testing, losing a maximum of 10-15% of their initial body weight. 
Weight was checked 2-3 times a week. In addition to the regular mouse chow, every mouse 
was given 2 to 3 of the reward pellets every day in the week before the experiment started 
to get accustomed to the taste. 
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2.3.3.3.3 Habituation phase 
Mice were placed into the test arena with house light and target lights off and 1 
pellet lying in each of the 5 target holes. They were allowed to explore the arena and eat the 
reward pellets for a maximum of 5 minutes per session. Time to explore all 5 holes, Time to 
eat all 5 pellets (300 s when all holes were not explored / all pellets were not eaten) and 
Number of pellets eaten per trial were recorded. If all 5 pellets were eaten before 5 minutes 
had passed, the trial was stopped. Each mouse underwent 9 habituation sessions over a 
period of 5 days. For details on all sessions see Table 4. After that, all female mice had an 
average of at least 2 eaten pellets per session, whereas male mice did not. In fact, half of the 
male mice had not eaten a single pellet during habituation phase. This bad performance was 
consistent and did not improve at all for the males all through the different phases of the 
experiment, which made it necessary to exclude them from the statistics due to obvious 
motivation difficulties. 
2.3.3.3.4 Autoshaping 1 phase 
In this phase, mice were again placed into the dark test arena. For each trial, 1 of the 
target lights was illuminated and a pellet was directly delivered into the hole. The trial ended 
when the mouse made a nose-poke into the hole (the target light was turned off as a 
consequence) and was succeeded by a 10 second inter-trial interval. A session ended after 
10 trials or 10 minutes, whichever came first. Variables recorded were Time to finish, 
Number of correct nose-pokes, the total Number of nose-pokes and Number of pellets eaten. 
Mice underwent 5 daily Autoshaping 1 sessions before moving on to Autoshaping 2. 
2.3.3.3.5 Autoshaping 2 phase 
The Autoshaping 2 phase was very similar to the Autoshaping 1 phase, with the 
exception that pellets were only delivered into the target hole after a mouse made the 
correct nose-poke. Additionally to the variables from Autoshaping 1, the Number of pellets 
eaten correctly (i.e. directly after making the nose-poke into the correct hole) was recorded, 
since mice diverged immensely regarding that behavior. After 4 daily Autoshaping 2 
sessions, mice moved on to the experimental phase. 
2.3.3.3.6 Experimental phase with 20 s stimuli 
The experimental phase was similar to the Autoshaping 2 phase with the exception 
that stimuli lasted only for 20 s and incorrect nose-pokes (into non-illuminated holes) were 
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penalized with a 10 s time-out with house light on. After the 20 s stimulus a 5 s hold interval 
was introduced, in which the mouse could still respond and be rewarded, but the target light 
was not on. A false nose-poke was penalized with a 10 s time-out with house light on. The 
Number of premature nose-pokes (nose-pokes during inter-trial intervals) was additionally 
taken as a variable. 10 sessions were performed over a period of 7 days. 
2.3.3.3.7 Test Trial with 9 s stimuli 
After the last experimental 20 s stimuli phase, one single test trial session was done 
with every mouse to check for performance under faster circumstances. Each trial was 9 
seconds long, with a 1 s hold interval, followed by 8 seconds of inter-trial interval. A false 
nose-poke was penalized with a 5 s time-out with house light on. 
 
Table 4: Phases of the modified 5-choice-serial-reaction-time-task 
Phase 
Stimulus 
duration 
Hold 
Inter-trial 
interval 
Timeout 
Number of 
trials 
Number of 
sessions 
Time 
Habituation ---- ---- ---- ---- ---- 9 300 s 
Autoshaping 1 
till nose-
poke 
occurs 
---- 10 s ---- 10 5 300 s 
Autoshaping 2 
till nose-
poke 
occurs 
---- 10 s ---- 10 4 300 s 
Experimental 20 s 5 s 8 s 10 s 10 10 600 s 
Test Trial 9 s 1  8 s 5 s 15 1 300 s 
 
2.3.3.4 Forced-Swim Test (FST) 
The FST was performed in a 2 l glass beaker, filled with water (26 ± 2 °C) to the 
1600ml mark. The mice were picked up by their tail and individually placed in the beaker. 
Behavior was recorded for 5 min. After that, the mouse was taken out of the beaker and 
returned to its home cage. Mobility and immobility were recorded as well as the latency to 
the first immobility. The water was changed between animals. 
2.3.3.5 Resident-Intruder Paradigm (RI) 
The RI test was exclusively performed with male mice. Cages were changed 5 days 
before the test, so that the homecage of an animal (the resident) sufficiently smelled like the 
respective animal and thus could be considered “home territory”. Everything except bedding 
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and mouse was removed from the cage, a slightly smaller male wild-type Snap25 (the 
intruder) mouse was also placed into the cage and behavior of the resident was recorded for 
10 min. Since not a single mouse in the experiment behaved in any way aggressive towards 
the intruder mouse during this test there were no variables recorded. 
2.3.3.6 Methylphenidate Challenge Open Field 
The repeated long-term OF was performed in two 60 minute sessions, spaced three 
weeks apart, the same way as explained in 2.3.3.1. Before the second session, half of the 
wild-type mice and half of the heterozygous mice (8 each) were given 45 mg/kg MPH orally 
on a chocolate flavored cereal flake (see 2.1.2). The main parameter taken was the distance 
travelled. After each mouse, the arena was thoroughly cleaned with disinfectant. 
2.3.4 Brain dissection 
Brains were dissected as described in 2.1.4. The frontal cortex, the striatum and the 
hippocampus were taken as regions of interest. Regions were collected in Eppendorf Safe-
Lock Biopur 1.5 ml tubes (sterile, free of Pyrogen, RNase, DNA and ATP; Eppendorf AG, 
Hamburg, Germany) and stored at -20 °C until RNA extraction for the qRT-PCR. 
2.3.5 Corticosterone assays and adrenal weights 
The corticosterone analysis from blood was done by Daniel van den Hove at 
Maastricht University in the Netherlands using a radioimmunoassay previously described 
(van den Hove et al., 2006). To assess a further measure for stress, adrenals were weighed 
on precision scales. 
2.3.6 Quantitative real-time PCR 
RNA isolation, purification and removal of potential remaining genomic DNA from 
mouse brain tissue was performed by Theresia Töpner using the RNeasy Mini Kit (QIAGEN, 
Hilden, Germany), substituting the lysis buffer for PeqGold RNA Pure (PEQLAB, Erlangen, 
Germany). RNA concentration and quality were determined using the automated 
electrophoresis system Experion™ (Biorad, Munich, Germany) as described in the 
corresponding manual. 3 samples were excluded due to an RQI (RNA quality indicator; 
according to the Experion™ system) value of less than 7. 
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Table 5: Self-designed primer pairs for reference genes and genes of interest used for quantitative real-time 
PCR; Genes of interest are highlighted in grey; 
Gene Primer Sequence 5’ – 3’ 
Sdha 
MmSDHA-F GGACAGGCCACTCACTCTTAC 
MmSDHA-R CACAGTGCAATGACACCACG 
Pgk 
MmPGK-F TCGCTTTCCAACAAGCTGAC 
MmPGK-R TTGATGCTTGGAACAGCAGC 
Tbp 
MmTBP-F ACCTTATGCTCAGGGCTTGG 
MmTBP-R TGCCGTAAGGCATCATTGGA 
B2m 
MmB2M-F ACTGACCGGCCTGTATGCTA 
MmB2M-R CAATGTGAGGCGGGTGGAA 
Tfrc 
MmTFRC-F TCCGCTCGTGGAGACTACTT 
MmTFRC-R ACATAGGGCGACAGGAAGTG 
Hprt 
MmHPRT-F TGCTGACCTGCTGGATTACA 
MmHPRT-R TTTATGTCCCCCGTTGACTGA 
Snap25 
Mm_Snap25-F ATCAGTGGTGGCTTCATCCG 
Mm_Snap25-R CATATGGCGGAGGTTTCCGA 
Drd2 
Mm_Drd2-F ATGCCCTGGGTCGTCTATCT 
Mm_Drd2-R TACCTGTCGATGCTGATGGC 
Maoa 
Mm_Maoa-F TCGGGAGAATTTTACCCAAACCA 
Mm_Maoa-R AACTCTATCCCGGGCTTCCA 
Comt 
Mm_Comt-F ACCGCTACCTTCCAGACACA 
Mm_Comt-R GCCAGGAAGTCAGGGGTTC 
 
2 µg of total RNA were reversely transcribed into complementary DNA using the 
iScript™ cDNA synthesis kit (Biorad, Munich, Germany). After the reverse transcription 
reaction the cDNA was diluted 1:5 with 1x TE buffer. 
For quantitative real-time PCR, the SYBR® Select Master Mix (Life Technologies 
GmbH, Darmstadt, Germany) and either Quantitec (QIAGEN, Hilden Germany) primer assays 
(only in the case of Nos1: Mm_Nos1_2_SG) or self-designed primers (for Snap25, Mao-a, 
Drd2 and Comt; see Table 5) were used. In a Pilot study to find suitable reference genes Sdha 
(Succinate Dehydrogenase Complex, Subunit A), Pgkh (phosphoglycerate kinase), Tbp (TATA 
box binding protein), B2m (beta-2-microglobulin), Tfrc (transferrin receptor) and Hprt 
(hypoxanthine phosphoribosyltransferase) were tested. All primers for this Pilot study were 
self-designed (see Table 5). Finally, Sdha and Pgk were selected as the most stable reference 
genes to go into the analysis. Each 10 µl reaction volume contained 5 µl 1 x SYBR® Select 
Master Mix, 1x Quantitec primers or 500 nM of the oligonucleotide primer and 1 µl of the 
diluted cDNA. PCR and fluorescence measurements were run in the CFX384™ Real-Time PCR 
detection system (Biorad, Munich, Germany). The reaction conditions can be found in Table 
6. 
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Table 6: Quantitative real-time PCR protocol 
Step Temperature Time Repeats 
1 50 °C 2 min 1 
2 95 °C 2 min 1 
3 95 °C 15 s 
40 cycles 
4 60 °C 1 min 
5 95 °C 10 s 1 
6 65–95 °C 5 s 60 x 0.5 °C steps 
 
qRT-PCR was also done by Theresia Töpner, using 96-well plates. Samples were 
tested in duplicates and every 96 well plate contained 4 inter-run calibrator wells and one 
negative H2O control well. 
Data analysis and normalization was done by Lena Weißflog. PCR efficiencies were 
determined based on raw data using the software tool LinReg. Baseline correction of the 
threshold cycle (Ct) values was performed with the CFX Manager™ software (Biorad, 
Munich, Germany). This software also calculates relative quantities (Q values), which were 
normalized based on the relative quantities of the two considered reference genes. 
2.3.7 Statistical analysis 
Every analysis for the G x E study was first done with a 3-way ANOVA with sex 
(male/female), stress (control/maternal separation) and genotype (wild-type/heterozygous) 
as factors. In the event of significant sex effects, data was split for sexes and two 2-way 
ANOVAs (genotype and stress as factors) were calculated. When there was no significant sex 
effect, data analysis was redone with a 2-way ANOVA (genotype and stress as factors). For a 
significant genotype x stress interaction, 4 Bonferroni-Holm adjusted t-tests were done 
(wild-type Control vs wild-type MS / heterozygous Control vs. heterozygous MS / wild-type 
Control vs. heterozygous Control / wild-type MS vs heterozygous MS). 
For the 5-Choice-Serial-Reaction-Time-Task, only the female data was taken into 
account, since males were unable to learn the task adequately enough to go into the test 
trial. Thus, only genotype and stress remained as between factors. For all stages of the 
experiment except for the test trial, the number of the trial served as within factor. For the 
within factor and all its interactions, the Greenhouse-Geisser correction was used in the 
event of a violation of sphericity. 
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3 Results 
3.1 MPH study 
3.1.1 Activity 
 
  
Figure 7: Behavioral results (total distance travelled without baseline) from the ip (left) and oral (right) MPH 
groups; * signify statistically significant (p<0.05) differences as compared to the control group (0 mg/kg) 
Both the injected and the oral MPH animals show the expected elevated activity with 
higher doses of MPH (see Figure 7). In addition, also for both the ip and oral group, activity 
declines for the highest doses that could be construed as overdosing. The ANOVA results 
show that the change in activity with MPH is highly significant for both administration 
methods (see Table 7). 
Table 7: ANOVA results for total distance travelled both during baseline and after drug administration for the 
different MPH dosage groups 
Dependent variable Effect F Significance 
Distance travelled 
baseline 
Different dosage groups 
intraperitoneal F(5;36) 
0.581 p = 0.714 
Different dosage groups  
oral F(4;30) 
2.216 p = 0.091 
Distance travelled 
after MPH 
Different dosage groups 
intraperitoneal F(5;36) 
10.123 p < 0.001 
Different dosage groups 
oral F(4;30) 
8.952 p < 0.001 
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3.1.2 HPLC 
3.1.2.1 ANOVA results 
Table 8 and Table 9 summarize the results from the oral and i.p. ANOVAs of the 
dosage effects for dopamine, serotonin, norepinephrine and their metabolite quotients both 
in the hippocampus and the striatum. Significant effects were followed up with Scheffé post-
hoc tests of every dose compared to the respective control condition (0 mg/kg), these 
results can be found in 3.1.2.2. to 3.1.2.7.. 
Table 8: ANOVA results for the i.p. dosage effects of MPH on neurotransmitter concentrations in the frontal 
cortex and the striatum 
Intraperitoneal Dependent variable F(5;36) Significance 
Frontal cortex 
Dopamine 1.380 p = 0.255 
(HVA + DOPAC) / DA 6.326 p < 0.001 
Serotonin 6.192 p < 0.001 
5HIAA/5HT 14.073 p < 0.001 
Norepinephrine 2.316 p = 0.064 
MHPG/NA 2.550 p = 0.045 
Striatum 
Dopamine 4.463 p < 0.001 
(HVA + DOPAC) / DA 10.155 p < 0.001 
Serotonin 6.121 p < 0.001 
5HIAA/5HT 28.314 p < 0.001 
Norepinephrine 2.296 p = 0.066 
MHPG/NA 1.501 p = 0.214 
 
 
Table 9: ANOVA results for the oral dosage effects of MPH on neurotransmitter concentrations in the frontal 
cortex and the striatum 
Oral Dependent variable F(4;30) Significance 
Frontal cortex 
Dopamine 1.534 p = 0.218 
(HVA + DOPAC) / DA 7.906 p < 0.001 
Serotonin 2.959 p = 0.036 
5HIAA/5HT 1.689 p = 0.178 
Norepinephrine 1.252 p = 0.311 
MHPG/NA 0.343 p = 0.847 
Striatum 
Dopamine 3.711 p = 0.014 
(HVA + DOPAC) / DA 4.100 p = 0.009 
Serotonin 1.038 p = 0.404 
5HIAA/5HT 0.483 p = 0.748 
Norepinephrine 1.090 p = 0.379 
MHPG/NA 0.381 p = 0.820 
 
Results 
27 
 
3.1.2.2 Dopamine in the frontal cortex 
 
  
  
Figure 8: Dopamine concentrations and the respective metabolite quotients for the different i.p. and oral 
doses in the frontal cortex; ** : p<0.01, * : p<0.05, # : p<0.1; 
 
Dopamine concentration in the frontal cortex peeks at 7.5 mg/kg and 30 mg/kg for 
i.p. and oral administration, respectively, but not significantly, even though all of the main 
effects for dopamine and its metabolite quotient are significant in the ANOVA. At higher 
doses, the dopamine levels decline again for both forms of administration. The 60 mg/kg 
oral dose is the only one in which the metabolite quotient significantly deviates from the 
control condition. Direction-wise the two graphs are again very similar, although the 
absolute levels are rather different. 
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3.1.2.3 Dopamine in the striatum 
 
 
 
  
Figure 9: Dopamine concentrations and the respective metabolite quotients for the different i.p. and oral 
doses in the striatum; ** : p<0.01, * : p<0.05, # : p<0.1; 
 
Though all dopamine/striatum related effects in the ANOVA are significant, there are 
no significant post-hoc effects. Especially in the oral condition no directionality is visible. The 
same seems to be true for the oral quotient, although higher doses (90 mg/kg) significantly 
lower the ratio from metabolites to neurotransmitter. For the i.p. quotient, a dose of 15 
mg/kg significantly increases the ratio. Overall, absolute levels vary considerately between 
oral and i.p. administration. 
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3.1.2.4 Serotonin in the frontal cortex 
 
  
  
Figure 10: Serotonin concentrations and the respective metabolite quotients for the different i.p. and oral 
doses in the frontal cortex; ** : p<0.01, * : p<0.05, # : p<0.1; 
 
Absolute levels for serotonin and metabolite quotient in the frontal cortex are very 
different between oral and i.p. administration. Also the directions of the graphs are quite 
divergent. For the i.p. group, serotonin levels go up with smaller doses whereas in the oral 
group they go down. Concerning the metabolite quotient, the oral group does not reach 
significance on the whole in the ANOVA. In contrast, medium concentrations of i.p. MPH 
significantly enhance the quotient. 
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3.1.2.5 Serotonin in the striatum 
 
  
  
Figure 11: Serotonin concentrations and the respective metabolite quotients for the different i.p. and oral 
doses in the striatum; ** : p<0.01, * : p<0.05, # : p<0.1; 
 
Regarding serotonin levels and its metabolite quotient in the striatum, oral MPH 
administration does not have a statistically significant effect in the ANOVA. In contrast, i.p. 
MPH administration alters striatal serotonin levels and, most significantly, its metabolite 
quotient at a dose of 15 mg/kg. Again, basal serotonin levels are very dissimilar between the 
i.p. and the oral group. 
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3.1.2.6 Norepinephrine in the frontal cortex 
 
  
  
Figure 12: Norepinephrine concentrations and the respective metabolite quotients for the different i.p. and 
oral doses in the frontal cortex; ** : p<0.01, * : p<0.05, # : p<0.1; 
 
Only in the i.p. group norepinephrine levels reach marginal significance in the 
ANOVA, though no differences occur in the post-hoc tests between dosages. Overall, neither 
i.p. nor oral MPH seems to massively affect norepinephrine levels or the 
metabolite/norepinephrine quotient in the frontal cortex. Absolute levels between the oral 
and the i.p. condition don’t differ drastically. 
 
 
Results 
32 
 
3.1.2.7 Norepinephrine in the striatum 
 
  
  
Figure 13: Norepinephrine concentrations and the respective metabolite quotients for the different i.p. and 
oral doses in the striatum; ** : p<0.01, * : p<0.05, # : p<0.1; 
 
The same as in the frontal cortex, norepinephrine only reaches marginal significance 
in the i.p. condition in the striatum, again with no significant post-hoc results. Also similar to 
the results from the frontal cortex, MPH administration at the dosages tested does not seem 
to greatly influence norepinephrine levels and the metabolite quotient on the whole in the 
striatum. 
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3.2 Pilot Study COGITAT Holeboard System 
 
Table 10: Results from the discussed variables of the COGITAT Holeboard task; >/< signify significant results 
(p<0.05) from the Scheffé post hoc test after a significant main effect in the ANOVA; M: metrifonate / 
S: scopolamine / V: vehicle 
Parameter 
Total distance travelled n.s. 
Pellets eaten M > V > S 
Working memory errors, total M,V < S 
 
Table 10 summarizes the ANOVA results from the three variables discussed. As it was to be 
expected, there were no statistically significant differences between the different treatment 
groups when it came to locomotion, although the scopolamine treated group numerically 
travelled longer distances than the other two in the beginning (Figure 14). 
 
Figure 14: Total distance travelled for the different groups (Vehicle, Scopolamine, Metrifonate) over the 30 
trials of the COGITAT Holeboard test 
The variable most successful in separating between groups was the acquisition 
variable “pellets eaten”. Metrifonate treated animals find and eat significantly more reward 
pellets than the vehicle control group, whereas scopolamine treated animals find and eat 
significantly less pellets than the vehicle group (Table 10). However, this effect seems 
numerically most pronounced in the first 6 trials of the experiment (see Figure 15). 
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Figure 15: Number of pellets eaten for the different groups (Vehicle, Scopolamine, Metrifonate) over the 30 
trials of the COGITAT Holeboard test 
When it comes to working memory errors, the vehicle and the metrifonate group did 
not differ from each other, but both groups of animals made significantly fewer errors than 
the scopolamine treated group (Figure 16; Table 10). 
 
Figure 16: Working memory errors for the different groups (Vehicle, Scopolamine, Metrifonate) over the 30 
trials of the COGITAT Holeboard test 
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3.3 G x E study 
3.3.1 Behavior 
3.3.1.1 Long-Term Open Field 
Table 11 summarizes the ANOVA results for both the first and the second Open Field 
test. The environmental manipulation does not reach the significance level for either of the 
two sessions. But whereas in OF1 there is no difference between the two Genotypes, in OF2 
the main effect Genotype is at least marginally significant (p<0.1). Interestingly, in both OF1 
and OF2 the G x E interaction is significant. 
Table 11: ANOVA results for the total distance travelled in Open Field 1 and 2 
 Effect F(1;72) Significance 
Distance travelled 
OF1 
Genotype 0.156 p = 0.694 
Environment 1.841 p = 0.179 
G x E 5.384 p = 0.023 
Distance travelled 
OF2 
Genotype 3.815 p = 0.055 
Environment 0.660 p = 0.419 
G x E 4.594 p = 0.036 
 
  
Figure 17: Distance travelled in the first (OF1, left) and second (OF2 right) one-hour Open Field test; Data are 
presented as means +/- SEM; **: p<0.01 / *: p<0.05 / #: p<0.1 
OF1: The Bonferroni-Holm adjusted post-hoc t-tests reveal that though wild-type 
mice were significantly more active when they were subjected to MS, heterozygous mice 
remain on the same activity level. Heterozygous stressed mice are also significantly less 
active than stressed wild-type mice (Figure 17). 
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OF2: In the control group, heterozygous mice are more active than wild-type mice, 
but not in the MS group. As in OF1, for the wild-types the early-life stress has an enhancing 
effect on activity, but there is no difference for the heterozygous animal. 
3.3.1.2 Light-Dark-Box 
Table 12 summarizes the ANOVA results for the two most important measurements 
from the LDB. Time spent in the lit compartment did not reach significance for either the 
main effects or the interaction, but the latency to enter the lit compartment is significantly 
different between the two environment conditions and even marginally significant for the 
interaction of genotype and environment. 
Table 12: ANOVA results for the Light-Dark-Box 
 Effect F(1;72) Significance 
Time lit zone 
Genotype 0.315 p = 0.577 
Environment 1.750 p = 0.190 
G x E 1.243 p = 0.269 
Latency to lit zone 
Genotype 0.039 p = 0.844 
Environment 14.394 p < 0.001 
G x E 2.849 p = 0.096 
 
 
Figure 18: The latency to enter the lit zone of the Light-Dark Box 
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Figure 18 shows that independent from the genotype animals from the MS group 
take longer to enter the lit compartment. Even though the post-hoc tests don’t reach 
significance, the marginally significant effect for the interaction seems to stem from the 
numerical difference between the heterozygous animals in the two environmental groups. 
3.3.1.3 Modified 5-Choice-Serial-Reaction-Time-Task 
3.3.1.3.1 Habituation 
The ANOVA results from selected parameters of the habituation phase of the 5CSRTT 
can be found in Table 13. Heterozygous animals are marginally faster to inspect all 5 holes 
than the wild-types (means not shown), and although the trial effect almost reaches 
significance (meaning the time on the whole goes down over trials) this is overshadowed by 
a strong effect for trial x environment which shows that although the time to inspect all 
holes goes down over trials for the control group, it remains static for the MS group (means 
not shown). The same is true for the trial x environment effect for the total number of nose-
pokes, but with the control group making more and more nose-pokes over trial while the MS 
group stagnates. 
Table 13 : ANOVA results for the Habituation phase of the 5CSRTT 
  Effect F Significance 
Time to inspect 
all holes 
between 
F(1;35) 
Genotype 3.247 p = 0.080 
Environment 0.284 p = 0.597 
G x E 0.001 p = 0.982 
within 
F(4.892;171.234) 
Trial 2.247 p = 0.053 
Trial x G 0.830 p = 0.528 
Trial x E  6.111 p < 0.001 
Trial x G x E 0.795 p = 0.552 
Number of nose-
pokes 
between 
F(1;35) 
Genotype 1.797 p = 0.189 
Environment 0.001 p = 0.973 
G x E 3.117 p = 0.086 
within 
F(3.553;124.363) 
Trial 1.436 p = 0.230 
Trial x G 0.694 p = 0.581 
Trial x E 4.805 p = 0.002 
Trial x G x E 0.959 p = 0.425 
Number of 
pellets eaten 
between 
F(1;35) 
Genotype 0.983 p = 0.328 
Environment 2.644 p = 0.113 
G x E 0.285 p = 0.597 
within 
F(4.746;166.096) 
Trial 6.745 p < 0.001 
Trial x G 0.754 p = 0.578 
Trial x E 13.238 p < 0.001 
Trial x G x E 1.357 p = 0.245 
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Exemplary for the many significant trial x environment interactions in the habituation 
phase, mean data for the parameter “pellets eaten” are shown here (Figure 19). The left side 
shows the control groups, for which the number of rewards consumed increases over time, 
as it can be expected when learning a new task. For the maternal separation groups (right 
side), the number of pellets eaten remains the same or even goes down a little. 
  
Figure 19: Pellets eaten for the 9 sessions of the habituation phase; Control group on the left, MS group on 
the right; 
 
3.3.1.3.2 Autoshaping 1 
The same as in the habituation phase, in Autoshaping 1 the predominant effects are 
the trial x environment interactions, which overshadow the simple main effects for trial and 
environment (see Table 14). For example, the number of total nose-pokes goes down over 
time for the control groups (as it is to be expected when the task is accurately learned and 
less nose-pokes are required to reach the goal), but up for the MS groups (means not 
shown). As an example, the parameter “number of pellets eaten” is shown in Figure 20. Here 
the main effect environment can be seen (Control groups eat more rewards than the MS 
groups), but also the trial x environment interaction (Control groups eat a constant of 
around 9 pellets per session, whereas MS groups start at around 3 and work their way up to 
around 7 over sessions. 
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Table 14: ANOVA results for the Autoshaping 1 phase of the 5CSRTT 
  Effect F Significance 
Time to finish 
between 
F(1;30) 
Genotype 0.796 p = 0.379 
Environment 16.072 p < 0.001 
G x E 0.069 p = 0.795 
within 
F(3.058; 91.727) 
Trial 22.537 p < 0.001 
Trial x G 0.999 p = 0.398 
Trial x E  2.642 p = 0.053 
Trial x G x E 1.329 p = 0.270 
Number of nose-
pokes 
between 
F(1;30) 
Genotype 0.013 p = 0.910 
Environment 13.469 p = 0.001 
G x E 0.732 p = 0.399 
within 
F(2.927;87.807) 
Trial 0.612 p = 0.605 
Trial x G 1.174 p = 0.324 
Trial x E 4.755 p = 0.004 
Trial x G x E 0.790 p = 0.500 
Number of 
correct nose-
pokes 
between 
F(1;30) 
Genotype 0.279 p = 0.601 
Environment 20.287 p < 0.001 
G x E 0.507 p = 0.482 
within 
F(3.453;103.583) 
Trial 11.331 p < 0.001 
Trial x G 0.491 p = 0.715 
Trial x E 5.668 p = 0.001 
Trial x G x E 0.510 p = 0.702 
Number of 
pellets eaten 
between 
F(1;30) 
Genotype 0.343 p = 0.562 
Environment 34.599 p < 0.001 
G x E 0.385 p = 0.540 
within 
F(2.921;87.618) 
Trial 18.780 p < 0.001 
Trial x G 0.483 p = 0.690 
Trial x E 9.272 p < 0.001 
Trial x G x E 0.337 p = 0.794 
 
  
Figure 20: Pellets eaten for the 5 sessions of the Autoshaping 1 phase; Control group: left; MS group: right; 
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3.3.1.3.3 Autoshaping 2 
In the Autoshaping 2 phase, the predominant effect was the main effect for trial, 
which can be found in all of the parameters in Table 15. Interestingly, the new parameter 
measured (pellets eaten correctly) was the only one to show a strong genotype effect, that is 
to say the wild-types ate more pellets directly after the correct response than the 
heterozygous animals, both for the MS and the control group (Figure 21). 
Table 15: ANOVA results for the Autoshaping 2 phase of the 5CSRTT 
  Effect F Significance 
Time to finish 
between 
F(1;30) 
Genotype 0.648 p = 0.427 
Environment 0.482 p = 0.493 
G x E 0.211 p = 0.650 
within 
F(2.240;67.214) 
Trial 3.136 p = 0.044 
Trial x G 0.351 p = 0.729 
Trial x E  0.498 p = 0.631 
Trial x G x E 1.401 p = 0.253 
Number of nose-
pokes 
between 
F(1;30) 
Genotype 0.789 p = 0.381 
Environment 0.430 p = 0.517 
G x E 2.615 p = 0.116 
within 
F(2.748;82.443 
Trial 9.412 p < 0.001 
Trial x G 0.707 p = 0.539 
Trial x E 1.559 p = 0.209 
Trial x G x E 1.459 p = 0.234 
Number of 
correct nose-
pokes 
between 
F(1;30) 
Genotype 0.488 p = 0.490 
Environment 0.676 p = 0.417 
G x E 1.703 p = 0.202 
within 
F(2.716;81.489) 
Trial 3.299 p = 0.028 
Trial x G 0.282 p = 0.819 
Trial x E 1.292 p = 0.283 
Trial x G x E 0.614 p = 0.592 
Number of 
pellets eaten 
between 
F(1;30) 
Genotype 0.168 p = 0.685 
Environment 2.540 p = 0.121 
G x E 1.627 p = 0.212 
within 
F(2.579;77.373) 
Trial 2.670 p = 0.062 
Trial x G 0.483 p = 0.667 
Trial x E 1.191 p = 0.316 
Trial x G x E 0.650 p = 0.563 
Number of 
pellets eaten 
correctly 
between 
F(1;30) 
Genotype 8.620 p = 0.006 
Environment 0.542 p = 0.467 
G x E 1.086 p = 0.306 
within 
F(2.506;75.195) 
Trial 5.122 p = 0.005 
Trial x G 0.948 p = 0.409 
Trial x E 0.951 p = 0.408 
Trial x G x E 0.942 p = 0.412 
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Figure 21: Pellets eaten correctly for the 4 sessions of the Autoshaping 2 phase; Control group on the left, MS 
group on the right; 
3.3.1.3.4 Experimental phase with 20 s stimuli 
In the experimental phase, environmental effects were the most common (Table 16). 
MS animals made less overall nose-pokes, and also less premature and correct nose-pokes 
than the control group. Additionally, they ate fewer pellets and also failed more at eating 
them directly after the correct response (means not shown). The only genotype effect, albeit 
only marginally significant, could again be found in the new parameter “pellets eaten 
correctly”, in such a way that, again, the heterozygous animals were prone to not directly 
eating their pellets after the correct nose-poke (Figure 22). 
  
Figure 22: Pellets eaten correctly for the 10 sessions of the experimental 20s phase; wild-types on the left, 
heterozygous animals on the right; 
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Table 16: ANOVA results for the Ex20s phase of the 5CSRTT 
  Effect F Significance 
Time to finish 
between 
F(1;29) 
Genotype 0.072 p = 0.791 
Environment 1.509 p = 0.229 
G x E 0.019 p = 0.893 
within 
F(6.170;178.935) 
Trial 6.827 p < 0.001 
Trial x G 0.387 p = 0.891 
Trial x E  1.192 p = 0.312 
Trial x G x E 1.000 p = 0.428 
Number of nose-
pokes 
between 
F(1;29) 
Genotype 0.790 p = 0.381 
Environment 7.835 p = 0.009 
G x E 0.104 p = 0.749 
within 
F(5.765;167.174) 
Trial 7.094 p < 0.001 
Trial x G 0.730 p = 0.621 
Trial x E 1.957 p = 0.077 
Trial x G x E 0.669 p = 0.668 
Number of 
correct nose-
pokes 
between 
F(1;29) 
Genotype 0.192 p = 0.665 
Environment 5.517 p = 0.026 
G x E 0.340 p = 0.564 
within 
F(9;261) 
Trial 2.808 p = 0.004 
Trial x G 1.902 p = 0.052 
Trial x E 1.029 p = 0.417 
Trial x G x E 0.455 p = 0.904 
Number of 
premature nose-
pokes 
between 
F(1;29) 
Genotype 0.026 p = 0.874 
Environment 5.027 p = 0.033 
G x E 0.102 p = 0.752 
within 
F(9;261) 
Trial 4.495 p < 0.001 
Trial x G 0.467 p = 0.839 
Trial x E 2.200 p = 0.022 
Trial x G x E 0.726 p = 0.685 
Number of 
pellets eaten 
between 
F(1;29) 
Genotype 0.091 p = 0.765 
Environment 7.523 p = 0.010 
G x E 0.412 p = 0.526 
within 
F(9;261) 
Trial 3.071 p = 0.002 
Trial x G 2.124 p = 0.028 
Trial x E 1.059 p = 0.393 
Trial x G x E 0.570 p = 0.821 
Number of 
pellets eaten 
correctly 
between 
F(1;29) 
Genotype 3.293 p = 0.080 
Environment 7.445 p = 0.011 
G x E 1.092 p = 0.305 
within 
F(6.482;187.990) 
Trial 3.022 p = 0.006 
Trial x G 1.248 p = 0.281 
Trial x E 0.784 p = 0.593 
Trial x G x E 0.784 p = 0.592 
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3.3.1.3.5 Test Trial with 9 s stimuli 
Rather different than in the other phases of the experiment, in the test trial the 
genotype effects were the most common (Table 17). The only significant environment effect 
found was for the time to finish the experiment, for which the MS animals took longer than 
the controls (means not shown). Significant and marginally significant effects for genotype 
included the heterozygous animals making fewer correct nose-pokes (Figure 23, although 
not fewer on the whole), ate fewer pellets and also fewer directly after the correct response 
(Figure 24). 
Table 17: ANOVA results for the 9 s test trial of the 5CSRTT 
 Effect F(1;29) Significance 
Time to finish 
Genotype 0.592 p = 0.448 
Environment 4.392 p = 0.045 
G x E 0.226 p = 0.638 
Number of nose-pokes 
Genotype 1.354 p = 0.254 
Environment 0.916 p = 0.346 
G x E 2.383 p = 0.134 
Number of correct 
nose-pokes 
Genotype 4.133 p = 0.051 
Environment 2.565 p = 0.120 
G x E 0.650 p = 0.427 
Percent correct nose-
pokes 
Genotype 4.508 p = 0.041 
Environment 0.114 p = 0.738 
G x E 1.800 p = 0.190 
Number of premature 
nose-pokes 
Genotype 0.801 p = 0.378 
Environment 0.146 p = 0.705 
G x E 2.951 p = 0.096 
Number of pellets 
eaten 
Genotype 3.743 p = 0.063 
Environment 2.566 p = 0.120 
G x E 0.701 p = 0.409 
Number of pellets 
eaten correctly 
Genotype 7.054 p = 0.013 
Environment 2.572 p = 0.120 
G x E 0.112 p = 0.740 
 
Figure 25 depicts the number of premature nose-pokes, which is the only parameter 
with an – at least – marginally significant G x E interaction. Although not significant in the 
post-hoc test, this result seems to be based on the MS heterozygous animals, which, 
numerically, make fewer premature nose-pokes than all the other groups. 
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Figure 23: Percentage of correct nose-pokes in the test trial with 9 s stimuli 
 
 
 
 
 
Figure 24: Number of pellets eaten correctly in the test trial with 9 s stimuli 
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Figure 25: Number of premature nose-pokes in the test trial with 9 s stimuli 
 
3.3.1.4 Forced-Swim-Test 
Table 18 summarizes the ANOVA results for the Forced swim test, separately for 
males and females. The only significant result is the main effect for genotype in the males. 
As it can be seen in Figure 26 on the right side, heterozygous males spend significantly more 
time immobile independent from the stress group, arguing for elevated depression-like 
behavior. The same is not true for female mice. 
 
Table 18: ANOVA results for immobility times in the Forced Swim Test 
 Effect F males (1;26)/females (1;28) Significance 
Immobility time 
males 
Genotype 11.459 p = 0.002 
Environment 0.752 p = 0.394 
G x E 0.652 p = 0.427 
Immobility time 
females 
Genotype 0.572 p = 0.456 
Environment 0.197 p = 0.661 
G x E 1.833 p = 0.187 
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Figure 26: Time spent immobile in the Forced Swim Test (males on the right, females on the left) 
 
3.3.1.5 Resident-Intruder-Paradigm 
Since no mouse attacked another in the Resident-Intruder-Paradigm, data could not 
be evaluated due to the variation being equal to zero. 
 
3.3.1.6 Methylphenidate Challenge Open Field 
In the MPH challenge both the main effects and the interaction reached at least 
marginal significance (Table 19). The strongest effect was seen for the MPH treatment which 
enhanced activity overall, as it was to be expected. The marginal significance for the 
genotype by treatment interaction can numerically be explained from the more pronounced 
increase in activity after MPH administration for the heterozygous animals (Figure 27). 
Table 19: ANOVA results for distance travelled in the Open Field after MPH challenge 
 Effect F(1;27) Significance 
Distance travelled OF 
Genotype 3.555 p = 0.070 
MPH 8.564 p = 0.007 
Genotype x MPH 3.109 p = 0.089 
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Figure 27: Distance travelled after the consumption of a cereal flake with 45 mg/kg MPH or water 
 
3.3.2 Quantitative Real-Time Polymerase Chain Reaction 
3.3.2.1 Snap25 
 
Snap25 expression was significantly enhanced in all three analyzed brain regions (see 
Table 20 and Figure 28). Numerically, wild-types expressed almost twice the amount of 
Snap25 mRNA as heterozygous animals. 
 
Table 20: ANOVA results for Snap25 expression 
Snap25 Effect F(1;70) Significance 
Frontal cortex 
Genotype 276.313 p < 0.001 
Environment 0.034 p = 0.855 
G x E 0.275 p = 0.602 
Hippocampus 
Genotype 330.673 p < 0.001 
Environment 0.074 p = 0.787 
G x E 0.596 p = 0.443 
Striatum 
Genotype 204.608 p < 0.001 
Environment 0.097 p = 0.756 
G x E 4.333 p = 0.041 
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Figure 28: Snap25 expression (independent of stress group) in the Frontal cortex, the Hippocampus and the 
Striatum of Snap25 +/+ and +/- mice 
 
3.3.2.2 Comt 
 
Table 21: ANOVA results for Comt expression 
Comt Effect F(1;71) Significance 
Frontal cortex 
Genotype 5.487 p = 0.022 
Environment 2.007 p = 0.161 
G x E 2.181 p = 0.144 
Hippocampus 
Genotype 0.632 p = 0.429 
Environment 4.432 p = 0.039 
G x E 0.155 p = 0.695 
Striatum 
Genotype 0.577 p = 0.450 
Environment 3.254 p = 0.075 
G x E 0.004 p = 0.949 
 
Comt expression in the frontal cortex depended significantly on the genotype; 
heterozygous animals expressed less Comt mRNA than wild-types. In the hippocampus and 
the striatum, the main effect environment reached at least marginal significance. In both 
cases, stressed animals were prone to lower expression levels (Table 21, Figure 29). 
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Figure 29: Comt expression in the Frontal cortex (top), the Hippocampus (bottom left) and the Striatum 
(bottom right) for both stress groups of Snap25 +/+ and +/- mice 
 
3.3.2.3 Maoa 
 
Table 22: ANOVA results for Mao-a expression 
Maoa Effect F(1;71) Significance 
Frontal cortex 
Genotype 9.251 p = 0.003 
Environment 0.080 p = 0.777 
G x E 3.398 p = 0.069 
Hippocampus 
Genotype 1.999 p = 0.162 
Environment 1.075 p = 0.303 
G x E 0.157 p = 0.693 
Striatum 
Genotype 0.688 p = 0.410 
Environment 0.169 p = 0.682 
G x E 2.579 p = 0.113 
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Maoa expression only was significantly altered in the frontal cortex, where the main 
effect for genotype was the strongest (Table 22): wild-types had higher expression levels 
than heterozygous animals (Figure 30). The marginal significance for the G x E interaction is 
numerically based on the fact that wild-types and heterozygous animals differ more strongly 
for the control group than for the MS group. 
 
  
Figure 30: Maoa expression in the Frontal cortex (top), the Hippocampus (bottom left) and the Striatum 
(bottom right) for both stress groups of Snap25 +/+ and +/- mice 
 
3.3.2.4 Drd2 
Except for a significant main effect of environment in the striatum, there are no 
effects to be found on Drd2 expression (Table 23). Stressed animals were lower in DRD2 
mRNA expression than controls (Figure 31). 
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Table 23: ANOVA results for Drd2 expression 
Drd2 Effect F(1;71) Significance 
Frontal cortex 
Genotype 0.654 p = 0.422 
Environment 2.209 p = 0.142 
G x E 0.094 p = 0.760 
Hippocampus 
Genotype 0.058 p = 0.811 
Environment 1.609 p = 0.209 
G x E 0.077 p = 0.783 
Striatum 
Genotype 1.154 p = 0.286 
Environment 5.170 p = 0.026 
G x E 2.024 p = 0.159 
 
 
 
  
Figure 31: Drd2 expression in the Frontal cortex (top), the Hippocampus (bottom left) and the Striatum 
(bottom right) for both stress groups of Snap25 +/+ and +/- mice 
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3.3.2.5 Nos1 
Nos1 expression was strongly affected in all three examined brain regions (Table 24). 
All three showed strongly significant main effects for environment, for all of which it was 
true that animals from the control group had higher levels of expression than the stressed 
group. In the frontal cortex, heterozygous animals expressed more Nos1 than wild-types, 
although this effect seems stronger in the non-stressed control group, probably due to the 
marginally significant G x E interaction (Figure 32). This interaction effect looks very similar 
to the significant one in the striatum, where heterozygous animals expressed significantly 
more Nos1 than wild-types in the control condition, but went down in expression 
significantly when stressed, whereas wild-types stayed at the same level (Figure 32). 
 
 
Table 24: ANOVA results for NOS1 expression 
Nos1 Effect F(1;71) Significance 
Frontal cortex 
Genotype 7.050 p = 0.010 
Environment 13.546 p < 0.001 
G x E 3.717 p = 0.058 
Hippocampus 
Genotype 0.142 p = 0.707 
Environment 8.776 p = 0.004 
G x E 0.709 p = 0.403 
Striatum 
Genotype 2.109 p = 0.151 
Environment 28.545 p < 0.001 
G x E 8.090 p = 0.006 
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Figure 32: Nos1 expression in the Frontal cortex (top), the Hippocampus (bottom left) and the Striatum 
(bottom right) for both stress groups of Snap25 +/+ and +/- mice 
 
3.3.3 Corticosterone Analysis and adrenal weights 
Heterozygous animals had significantly lower corticosterone plasma levels than wild-
types (Table 25, Figure 33) independent from the stress group, arguing for a dysregulation of 
the HPA axis. 
Table 25: ANOVA results for corticosterone levels in blood plasma 
 Effect F(1;71) Significance 
Corticosterone in 
plasma 
Genotype 3.967 p = 0.050 
Environment 0.043 p = 0.836 
G x E 0.063 p = 0.803 
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Figure 33: Post mortem corticosterone levels in blood plasma of all animals from the G x E study 
The adrenal weights in males were significantly dependent on the environment 
conditions (Table 26); stressed animals had lower adrenal weights than un-stressed controls 
(Figure 34). In females the environment did not play a role, but heterozygous animals had 
lower adrenal weights than wild-types (Figure 34). 
Table 26: ANOVA results for adrenal weights 
 Effect F(1;34) Significance 
Adrenal weight 
males 
Genotype 0.039 p = 0.844 
Environment 6.446 p = 0.016 
G x E 0.946 p = 0.338 
Adrenal weight 
females 
Genotype 12.594 p = 0.001 
Environment 2.422 p = 0.129 
G x E 0.665 p = 0.420 
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Figure 34: Post mortem adrenal weights of all animals from the G x E study; left: males; right: females 
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4 Discussion 
4.1 Pilot study MPH 
The MPH pilot study was performed to find an optimal dosage of MPH for potential 
mouse ADHD models in behavioral experiments both i.p. and oral. Although an effective 
dosage of MPH in patients with ADHD results in an enhanced focus and thus usually 
attenuates the symptom of hyperactivity, it acts as a stimulant in healthy subjects and is 
even known to lead to dependence in some cases (Kollins et al., 2001). Thus, in healthy 
control mice like the ones used in this pilot study, the expected effect of MPH was not 
decreased, but rather increased locomotor activity (Tilley & Gu, 2008). For both the i.p. and 
the oral group, MPH as expected significantly changed locomotor activity. In the former, the 
first significant dosage was 7.5 mg/kg and in the latter 15 mg/kg, whereas they peaked in 
activity at 30 mg/kg and 60 mg/kg, respectively. At doses higher than that, activity declined 
again for both i.p. and oral groups, making the two resulting graphs bell-shaped. This 
resembles graphs from studies researching critical dopamine levels and dopamine D1 
receptor activation (Goldman-Rakic, 2000; Seamans & Yang, 2004), which concluded that 
both too little and too much dopamine availability can have adverse effects, and an optimal, 
intermediate dopamine level is to be aimed for when medicating patients with deficiencies 
in the dopaminergic system. Since MPH acts as a dopamine / noradrenalin reuptake inhibitor 
and as such increases dopamine levels in the synaptic cleft, the bell-shaped graphs found 
here are in line with these conclusions. On the behavioral level, the optimal dosage for mice 
should be one that significantly and stably modifies the contemplated behavior. Thus 7.5 
mg/kg i.p. is here considered a good dose. The question of what is the best oral dose is a 
little more complicated to answer, since although the total distance travelled in the 15 
mg/kg oral group is very much like in the 7.5 mg/kg i.p. group, the time response over 90 
minutes is rather different (data not shown). In the 15 mg/kg oral group, activity after the 
first 30 minutes after drug application declines more than in the 7.5 mg/kg i.p. group and 
overall, the curve is flatter. In contrast, the graph for the 60 mg/kg oral group is not as flat 
and appears more stable, but exhibits some inconsistencies at the end of the 90 minutes 
with rather high activity peaks. Thus an intermediate dose of 45 mg/kg was chosen as the 
best oral dose and used in the Snap25 study. 
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For the HPLC analysis, the two brain regions of interest chosen were the frontal 
cortex (encompassing the prefrontal and the motor cortex) and the striatum, since 
frontostriatal pathways are implied in ADHD (Kasparek et al., 2013) and both the motor 
cortex and the nigrostriatal dopamine system are associated with motor function (Wise, 
2004). The neurotransmitters and metabolites investigated were DA, 5HT, NA and their 
metabolic turnovers, because MPH binds to the dopamine transporter, the norepinephrine 
transporter and the serotonin transporter in decreasing affinity (Gatley et al., 1996). 
Probably the most interesting result is DA in the frontal cortex where the curves are very 
similar for i.p. and oral, both in level and shape of the graphs. Numerically, they peak at 7.5 
mg/kg i.p. and 30 mg/kg oral, which is in line with the first doses that were effective 
behaviorally. The metabolic turnovers peak a 30 mg/kg i.p. and 60 mg/kg oral and decline at 
the higher doses, thus a bell-shaped curve results. Considering the work of Goldman-Rakic 
(2000) and Seamans & Yang (2004), it appears as though the optimal concentration of 
dopamine in the synaptic cleft and thus the optimal binding to dopamine receptors in the 
frontal cortex is achieved somewhere in the range of 7.5-30 mg/kg i.p. and 30-60 mg/kg oral. 
In the striatum, where dopaminergic neurotransmission should also affect motor function, 
since the nigrostriatal pathway projects into the dorsal striatum (Wise, 2004), the picture is 
quite different. While for i.p. doses the DA concentration values numerically peak at 1 mg/kg 
and the metabolic turnovers significantly peak at 15 mg/kg and then decline, the different 
oral doses do not change DA concentrations at all. The metabolic turnover is only affected at 
the highest dose of 90 mg/kg, which might well be an artefact. Seemingly, oral application of 
MPH in mice does not influence DA concentrations in the striatum. Another issue to address 
here is the marked difference in DA concentration between the oral and the i.p. 0 mg/kg 
groups. These differences can also be found for 5HT and NA in the frontal cortex and the 
striatum. Since none of these groups actually received an effective substance, the reason for 
this is probably founded on the application method. It is well known today that laboratory 
environment can influence behavioral tests in rodents (Crabbe, 1999). This includes for 
example temperature, lighting, housing and weather (Stille et al., 1968) and of course painful 
and stressful events like injections (Drude et al., 2011). It has been one major aim of this 
pilot study to establish a relatively stress-free oral application method. This appears to be 
not only important in regard to behavior, but also to basal neurotransmitter levels. 
Serotonin concentrations in the frontal cortex and the striatum are very different for the i.p. 
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and the oral groups. Apart from the control group differences in both brain regions, 5HT 
concentration in the frontal cortex goes up for 7.5 mg/kg i.p. and then down again, whereas 
it goes down for 10 mg/kg oral and then slightly up again. A similar picture can be seen in 
the striatum with an i.p. peak of 45 mg/kg but no effects oral. This could be an artefact of 
the lower baseline in the i.p. groups but also be based on the application method itself as 
the bioavailability for i.p. and oral application MPH is very different (Gerasimov et al., 2000). 
Additionally, it is possible that the time point of brain removal at about 100 minutes after 
the drug application was either too early or too late for the oral group and not at an 
effective level. For a future study, microdialysis might be a better method to investigate this 
on-line. Norepinephrine concentrations do not differ for either brain region or application 
method. 
4.2 Pilot study COGITAT 
The pilot study COGITAT Holeboard was carried out to modify and validate the 
system that had previously been validated in rats (Heim et al., 2000) and to assess the 
feasibility of this set-up as a measure of ADHD-like (endo-)phenotypes. The COGITAT 
Holeboard was able to assess activity and learning measures in mice. In contrast to the 
Morris Water Maze (Morris, 1984) where learning occurs under pressure as mice are forced 
to find an escape from the water as quickly as possible, the COGITAT system is based on 
motivational parameters. On the other hand, in mice this means having to put them on a 
restrictive diet, which also can act as a stressor (Guarnieri et al., 2012), as mice that are not 
hungry are hard to motivate. Even though food restriction has been reported to enhance 
memory function initially, it can also impair consolidation (Talhati et al., 2014). 
On the whole, cognitive enhancer treatment with metrifonate resulted in better 
performance, and also scopolamine treatment as means to disrupt memory mostly had the 
expected result. It was possible to simultaneously measure activity and reference / working 
memory with this set-up making up two of the three primary symptoms of ADHD. 
Unfortunately, the system is not equipped to measure any impulsive tendencies, which 
underlie more subtle mechanisms. Thus it was excluded from use in the Snap25 
Gene x Environment study. 
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4.3 G x E study 
 
Maternal separation protocol 
Maternal separation in rodents is an established model of early life stress and has 
been shown to affect neuronal activity, memory and gene expression (Nishi et al., 2013) 
even though behavioral effects are not consistent and very strain dependent (Millstein & 
Holmes, 2007). There are various protocols to be found in literature; here it was chosen to 
separate the pups from their mothers at a regular time during the light phase for 3 hours per 
day for the first 21 days of life. Pup mortality was even lower than the usual 32% that is 
found in laboratory C57BL/6 mice (Weber et al., 2013). 
 
Activity 
When only considering the non-stressed animals, heterozygous mice are not more 
active than wild-types in the first long-term OF, but are so in the second. This is not because 
they cover more distance in the second than in the first, but because they remain on the 
same level as in the first, although the situation is a familiar one. The same is not true for the 
wild-types, whose activity level goes down in the second OF session. This appears to be 
normal behavior, as it can also be seen in other studies doing repeated OF tests (see for 
expample Pan et al., 2008). Heterozygous animals do not show this decline in activity in a 
more familiar environment. In both sessions, the G x E interaction is significant, which 
apparently results from the fact that both MS stress and a heterozygous Snap25 deletion 
have enhancing effects on activity. This has previously been shown for the former in wild-
type C57BL/6 mice (Carlyle et al., 2012), and for the latter in combination with nicotine (Baca 
et al., 2013). In contrast to the study by Baca and colleagues (2013), environmental adversity 
in this study does not add to the enhanced activity effect of MS in heterozygous Snap25 
animals. On the contrary, in the first OF session MS heterozygous mice are significantly less 
active than MS wild-types. In the second session, all animals that either underwent MS or 
were heterozygous for Snap25 or both were similarly more active than control wild-types. 
Thus, it appears as tough in a somewhat familiar environment, both reduced levels of 
Snap25 and early life stress produce a slightly hyperactive phenotype in mice, but this effect 
does not intensify when both prerequisites are met simultaneously. 
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Learning / Attention / Impulsivity 
What kinds of effects were predominant in the 5CSRTT largely relied on the phase of 
the experiment. During the introduction to the task, namely in the habituation phase and 
the first Autoshaping phase, successfully acquiring the reward was based mainly on the 
animals’ exploration skills. The strongest effects found in both phases were environment 
effects and trial x environment interactions, no genotype effects became apparent. Unlike 
mice from the control group, MS animals did not increase the number of pellets they ate 
over sessions, but remained static or even declined. There are studies showing difficulties in 
the execution of learning-tasks in animals that were subjected to stressors both prenatally 
(Bustamante et al., 2010) and postnatally (Spinelli et al., 2013; Wang et al., 2014). Still, it is 
not clear if in this case the problem is a matter of cognitive skills or motivation, especially 
when taking into account the results from the next phase of the experiment: In the 
Autoshaping phase 2, environmental effects disappeared and only trial effects were 
apparent. The one crucial thing that changed in this phase was that the animals needed to 
actively trigger the reward. In contrast to the first two phases, this was equally easy or 
challenging for all groups when only the normal parameters were taken into account. But as 
many heterozygous Snap25 knockout mice were easy to identify on the 5CSRTT videos due 
to their increased activity (a parameter unfortunately not measured by the system), a means 
was found to include this nervous-looking behavior. The measure “number of pellets eaten 
correctly”, meaning pellets eaten directly after the correct nose-poke, was found adequate 
to map this agitated state: heterozygous animals significantly more often did not eat their 
reward directly after the correct response, but rather explored some more in the second it 
took for the reward pellet to fall into the hole. Since, statistically speaking, heterozygous 
mice made no more mistakes than the wild-types during this phase, random responses could 
not have caused this effect. It rather appears that it is a distinct feature of this genotype to 
be too active or too unwilling to wait for this short period of time. It has been known for 
some time that children with ADHD prefer small immediate rewards over larger delayed 
ones. This inability to wait has been termed “delay aversion” (Sonuga-Barke et al., 1992) and 
been proven to be an important feature of ADHD with neurophysiological correlates over 
the years (Wilbertz et al., 2013). Though the 5CSRTT is not adequate to completely uncover 
the complexity of delay aversion, it seems legitimate to speculate on a potential delay 
Discussion 
61 
 
aversion phenotype in Snap25 heterozygous knockout mice based on the new parameter 
“pellets eaten correctly”. In the experimental phase with 20 s stimuli, this parameter again 
reaches marginal significance. As in the other phases, there are some effects of environment 
identifying stressed mice as having the inferior learning skills. Interestingly, in the last test 
trial with 9 s stimuli, the most common effect found was not the environment, as in the 
other phases, but the genotype. The shorter stimuli appear to be able to uncover more 
about the heterozygous mice, namely that they made less correct nose-pokes, ate less 
pellets and less pellets correctly as in the two preceding phases. Shorter and thus more 
rapidly changing stimuli require more attentional resources when trying to react correctly to 
as many as possible, thus heterozygous mice showed inadequacy in this regard as well. 
When it comes to the most often used impulsivity measure in this test, the “number of 
premature nose-pokes”, hardly any effects were found in the different phases of the 
experiment. Only in the last test trial a marginally significant gene x environment interaction 
was uncovered, in which the heterozygous mice did not differ from wild-types under control 
conditions, but when they were stressed. In contrast to the other found effects, the stress 
caused them to make less premature nose-pokes, which is the opposite one would expect 
from an ADHD model. 
 
Depression related behavior 
Regarding depression-like behavior in the forced-swim test, remarkable sex-
differences were found. Females on the whole had higher levels of immobility time than 
males, independent from genotype or stress-group. This has been previously shown and is 
probably a result of estrogen in the brain and its impact on hippocampal nitric oxide levels 
(Hu et al., 2012). More interestingly, when sexes were regarded separately, female mice did 
not show any effect of genotype or environment, but male heterozygous mice spent 
significantly more time immobile than male wild-types, and thus showed more depression-
like behavior, no matter if they had been stressed in early life or not. However, it should not 
be disregarded that the forced-swim test was the second to last test in a relatively long 
series. As it has become clear that even normal laboratory routines are stressful for mice 
(Drude et al., 2011), it could be said that at the point in time of the testing, all mice were 
under the influence of chronic stress which could have masked an early-life stress effect. 
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Anxiety-like behavior 
In the Light-Dark-Box, no effects were found for the parameters “time in lit 
compartment” and “transitions between compartments”. The only significant effect could be 
found for environment in “latency to enter lit compartment”. Animals that had been 
subjected to early-life stress took significantly longer to enter the lit compartment for the 
first time and thus showed more anxiety-like behavior than non-stressed animals. This effect 
has previously been reported for different kinds of stressors (Kitaoka et al., 2013; Sarro et 
al., 2014) and is therefore not surprising. More interestingly, the gene x environment 
interaction reaches marginal significance. Although not significant in the post-hoc tests, it 
seems that heterozygous mice under control conditions were faster to enter the lit 
compartment than the wild-types and reacted more strongly to the stressor through even 
longer latency times. As this is similar to what is sometimes observed in humans with certain 
susceptibility genotypes (Caspi et al., 2003), it should be kept in mind. 
 
Aggression 
Aggression testing was unsuccessful because of the apparent low aggression levels in 
the mice tested, but also because of flaws in experimental design. Mice were single housed 
for a long period of time, mainly to make food restriction protocols easier in the 5CSRTT. 
Though single housing can sometimes be beneficial for aggression tests, it is detrimental 
when it is done for longer periods and can also lead to abnormal or even pathological forms 
of aggression (Miczek et al., 2001). Ideally, males should be housed with a female to display 
territorial aggression. Moreover, the test should be done repeatedly in order for aggressive 
behavior to stabilize (Newman et al., 2012). 
 
MPH challenge 
When testing a potential ADHD mouse model in an activity test with MPH, the 
expected result is that hyperactivity goes down and approximates a normal control level (see 
for example Zhu et al., 2014). This is sometimes called “paradoxical effect”, as MPH is a 
psychostimulant and in healthy controls leads to higher blood pressure and heart rate 
(Tomasi et al., 2011). However, apart from activity patterns, patients and controls react 
quite similarly to the drug (Rapoport & Inoff-Germain, 2002). In this study, the effect found 
was quite reversed. MPH administration significantly increased activity on the whole and the 
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marginal significant effect for the gene x MPH interaction is a result of the even higher 
increase in activity for the heterozygous mice as compared to the wild-types. Nonetheless, 
this difference is probably based on altered dopaminergic and noradrenergic signaling in the 
Snap25 heterozygous knockout mice, which is implied in ADHD, even if the directionality is 
wrong. 
 
Gene expression 
Genes investigated in the qRT-PCR - in addition to Snap25 itself to ascertain that 
genetic manipulation was effective - all have been previously associated with ADHD. Snap25 
expression was significantly decreased in all investigated brain regions in all heterozygous 
animals, independent from environment and gender, showing almost perfect dose-effect 
expression levels of about 50 % of wild-type expression. Comt and Maoa had similar 
expression patterns in the frontal cortex with significantly lower mRNA levels for the 
heterozygous animals. Since both Maoa and Comt are enzymes which are, among others, 
responsible for breaking down dopamine and norepinephrine, and frontostriatal pathways 
are implicated in ADHD (Banaschewski et al., 2010), these results are in line with a potential 
ADHD model. Then again, both the Maoa and the Comt knockout mouse display hypoactive 
behaviors, the former in the form of hypo-locomotion (Bortolato et al., 2009) and the latter 
in the form of decreased rearing behavior (Babovic et al., 2007), which is both not true for 
the Snap25 knockout mice in this experiment. Unfortunately, to date there are no studies on 
the effects of Maoa and Comt knockout on Snap25 expression. Seemingly, these three genes 
influence each other in a more complex fashion with interesting effects on locomotive 
behavior. The only dopamine receptor investigated was Drd2, the dopamine autoreceptor. 
Its expression was only dependent on the environment and not on the genotype. This 
environmental effect has previously been described in rats (Li et al., 2013), also with 
decreased expression rates in early-life stress animals. However, the most striking effects 
found in the qRT-PCR analysis were for Nos1 expression with G x E interactions in both the 
frontal cortex and the striatum. In both brain regions, Nos1 expression was higher for the 
control heterozygous animals than for the wild-type controls, but went down with MS for 
both genotypes to the same level. This multifaceted gene has been implicated in a great 
number of psychiatric (Franke et al., 2009; Reif et al., 2006; Reif et al., 2009) and 
neurological (Chabrier et al., 1999) disorders and its product’s substrate has countless 
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modes of action. This study found that Nos1 expression is both influenced by environmental 
stress and Snap25 levels in the striatum and the frontal cortex. It is therefore likely that Nos1 
levels are also causally involved in the behaviors seen here. 
 
Stress parameters 
Corticosterone levels did not differ between male and female mice on the whole, 
although this has often been described (see for example Coleman et al., 1998) but levels of 
heterozygous mice were approximately 30 % lower than those of wild-types, independent 
from stress group. Although this was not expected as altered corticosterone levels in 
stressed animals have been reported before (Roque et al., 2014), again the duration of the 
experimental series and the stress experienced through behavioral testing might be the 
reason for this lacking environmental effect. Lower corticosterone levels in heterozygous 
mice indicate a dysfunction of the hypothalamus – pituitary – adrenal (HPA) axis as a result 
of the genetic modification. Adrenals were weighed as a further measure of this complex 
circuitry and here the expected gender difference was found. Not only were female adrenals 
around twice as heavy as male adrenals, but the effects within these groups were rather 
different, when being looked at separately. Where for male mice differences were not based 
on genotype, but only on environment, for females it was the other way around: the 
adrenals of heterozygous females were much smaller than those of wild-type females. When 
comparing this with the corticosterone levels in serum, the question arises whether the non-
existent genotype difference there has its seeds in a gender bias, as most of the 
heterozygous animals from the MS group were females due to a breeding disequilibrium. 
5 Conclusion 
Two things were tried to accomplish in this thesis: Firstly, to evaluate different doses 
and different application methods of MPH on a behavioral and neurochemical level; 
Secondly, to thoroughly investigate heterozygous Snap25 knockout mice as a potential 
model for ADHD. 
Findings from the MPH pilot study suggest that even though it is possible to find i.p. 
and oral doses that correlate behaviorally in mice, the neurochemistry is mostly different. 
The questions arises which application method models application in humans better, 
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because even though a model might behaviorally fit with the human condition, the 
neurochemistry involved could be quite different. 
The G x E Snap25 study was able to uncover behavioral deficits in the heterozygous 
mice. In addition to a mild hyperactivity in a familiar environment, the mice showed elevated 
depression-like behavior and attenuated anxiety-like behavior. Moreover, some parameters 
from the 5CSRTT hint at an attentional inadequacy and some aspects of delay aversion. The 
stress parameters measured uncovered an imbalance in the HPA axis, which usually 
accompanies psychiatric disease, and qRT-PCR found expression changes in 3 genes that 
have been associated with ADHD. All these findings are in line with an ADHD model. 
However, MPH application had an effect that was contrary to the expected one but still 
elucidated deficits in systems tightly linked to the disorder. In conclusion, the heterozygous 
knockout of Snap25 in mice does not lead to full occurrence of ADHD-like symptoms, but 
nonetheless results in an endophenotype of increased activity and irritability which, 
considered together with the changes in gene expression, constitutes another step towards 
the understanding of not only ADHD, but also other psychiatric disorders. 
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